NZ618684B2 - Oxazepines as ion channel modulators - Google Patents

Oxazepines as ion channel modulators Download PDF

Info

Publication number
NZ618684B2
NZ618684B2 NZ618684A NZ61868412A NZ618684B2 NZ 618684 B2 NZ618684 B2 NZ 618684B2 NZ 618684 A NZ618684 A NZ 618684A NZ 61868412 A NZ61868412 A NZ 61868412A NZ 618684 B2 NZ618684 B2 NZ 618684B2
Authority
NZ
New Zealand
Prior art keywords
heteroaryl
aryl
alkyl
heterocyclyl
cycloalkyl
Prior art date
Application number
NZ618684A
Other versions
NZ618684A (en
Inventor
Britton Kenneth Corkey
Elfatih Elzein
Michael Graupe
Juan Guerrero
Robert H Jiang
Rao V Kalla
Dmitry Koltun
Xiaofen Li
Ruben Martinez
Eric Q Parkhill
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority claimed from PCT/US2012/045021 external-priority patent/WO2013006463A1/en
Publication of NZ618684A publication Critical patent/NZ618684A/en
Publication of NZ618684B2 publication Critical patent/NZ618684B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

The disclosure relates to compounds of formula I that are sodium channel inhibitors, wherein Y, Z R1, R3 and n are as described in the specification. The disclosure also relates to their use the treatment of various disease states, including cardiovascular diseases and diabetes. The cardiovascular disease may be atrial and ventricular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, pulmonary hypertension or intermittent claudication. Example compounds include: (R)-tert-butyl3-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1 ,4]oxazepin-5-ylamino)pyrrolidine-1-carboxylate, N-(cyclopropylmethyl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine, 5-(pyrrolidin-1-yl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepine N -cyclopropyl-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine N-benzyl-N-methyl-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine N-((3-fluoropyridin-2-yl)methyl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine N-(pyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine N-(cyclopropylmethyl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine (S)-tert-butyl 1-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-yl)pyrrolidin-3-ylcarbamate N-(2-(IH-imidazol-I-yl)ethyl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine (S)-N,N-dimethyl-1-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-yl)pyrrolidin-3-amine N-(pyridin-2-yl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][I,4]oxazepin-5-amine isease may be atrial and ventricular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, pulmonary hypertension or intermittent claudication. Example compounds include: (R)-tert-butyl3-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1 ,4]oxazepin-5-ylamino)pyrrolidine-1-carboxylate, N-(cyclopropylmethyl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine, 5-(pyrrolidin-1-yl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepine N -cyclopropyl-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine N-benzyl-N-methyl-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine N-((3-fluoropyridin-2-yl)methyl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine N-(pyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine N-(cyclopropylmethyl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine (S)-tert-butyl 1-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-yl)pyrrolidin-3-ylcarbamate N-(2-(IH-imidazol-I-yl)ethyl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine (S)-N,N-dimethyl-1-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-5-yl)pyrrolidin-3-amine N-(pyridin-2-yl)-7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][I,4]oxazepin-5-amine

Description

/045021 OXAZEPINES AS ION L MODULATORS Cross-Reference to Related Applications This application claims the benefit under 35 U.S.C. § 119(e) to US. Provisional Application Serial Number 61/503,980, filed on July 1, 2011, the entirety of which is incorporated herein by reference.
Field The present sure relates to novel compounds and to their use in the treatment of various diseases, including cardiovascular diseases and diabetes. The disclosure also relates to methods for preparation of the compounds and to pharmaceutical compositions comprising such compounds. ound The late sodium current (INaL) is a sustained component of the fast Na+ current of cardiac myocytes and neurons. Many common neurological and c conditions are ated with abnormal (INaL) enhancement, which contributes to the pathogenesis of both electrical and contactile dysfimction in mammals. See, for example, Pathophysiology and Pharmacology of the Cardiac “Late Sodium Current”, Pharmacology and Therapeutics 119 (2008) 326-339. Accordingly, compounds that selectively inhibit (INaL) in mammals are useful in treating such disease states.
One example of a selective inhibitor of (INaL) is RANEXA®, a compound ed by the FDA for the treatment of chronic stable angina is. RANEXA® has also been shown to be useful for the ent of a variety of cardiovascular es, including ischemia-reperfusion injury, arrhythmia and unstable angina, and also for the treatment of diabetes. It would be desirable to provide novel compounds that selectively inhibit INaL in mammals.
Summary Accordingly, typical embodiments the present disclosure provide novel compounds that function as late sodium channel blockers. In one embodiment, the disclosure provides compounds of Formula I: R1€EY\Z>' / OJ\(R3)n wherein: -Y-Z- is -C(=NR4)-NR2- or R6)=N-; R1 is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; wherein said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or aryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, -CN, -SF5, -Si(CH3)3, , -S-R20, -C(O)—R20, -C(O)-OR20, )(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-C(O)-OR22, )-S(=O)2-R26, -S(=O)2-R20, -O-S(=O)2-R20, 2-N(R20)(R22), C1_6 alkyl, c2_4 alkenyl, c2_4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1_6 alkyl, C2_4 alkenyl, C2_4 alkynyl, cycloalkyl, aryl, aryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, phenyl, heterocyclyl, heteroaryl, C1_6 alkyl, cycloalkyl, -N(R20)(R22), -C(O)-R20, -C(O)—OR20, -C(O)- N(R20)(R22), -CN and ; R2 is en, C145 alkyl, -C(O)-R20, -C(O)—OR26, -C(O)—N(R26)(R26), -N(R20)-S(=O)2-R20, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C145 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C1_6 alkyl, C2_4 alkynyl, halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN, oxo and -O-R20; wherein said C1_6 alkyl, lkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, lkyl, aryl, heterocyclyl or heteroaryl are optionally fiarther substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, -CF3, -N(R20)(R22), R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN, -S(O)2-R20 and —0— R20; nisO, l,2,3or4; each R3 is ndently C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and -O-R20; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further tuted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1- 6 alkyl, aralkyl, cycloalkyl, aryl, cyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, lkyl, aryl, heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group ting of halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and —0— R20; or two R3 attached to a common carbon atom form an oxo; or two R3 attached to a common or adjacent carbon atoms form a cycloalkyl or heterocyclyl; wherein said cycloalkyl or heterocyclyl are optionally filrther substituted with one, two or three substituents ndently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)—R20, -C(O)—OR20, -C(O)—N(R20)(R22), -CN and -O-R20; R4 is C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, aryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, )(R22), -C(O)-R20, -C(O)-OR20, -C(O)— N(R20)(R22), -CN and -O-R20; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are ally r substituted with one, two or three tuents independently selected from the group consisting of halo, -N02, C1- 6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are ally fiarther tuted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; or R2 and R4 can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said cyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, C1_6 alkyl, cycloalkyl, heteroaryl, -CN, -O-R20, -N(R20)(R22), -C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; and wherein said C1_6 alkyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -CN, -O-R20, C1_6 alkyl, aryl, and heteroaryl; R5 is hydrogen, C1_6 alkyl, cycloalkyl, aryl, aryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group ting of halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, OR20, -C(O)— N(R20)(R22), -CN and -O-R20; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1- 6 alkyl, aralkyl, cycloalkyl, aryl, cyclyl, aryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, cyclyl or heteroaryl are optionally fiarther substituted with one, two or three substituents independently selected from the group ting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20; R6 is C1_6 alkyl, cycloalkyl, aryl, aryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are ally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)— N(R20)(R22), -CN and ; wherein said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1- 6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, )(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally fiarther substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R2°)(R22), -C(0)-R2°, -C(0)-0R2°; or R5 and R6 can join together with the atom to which they are attached to form a cyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group ting of halo, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl, aryl, -CN, 0X0, R20, )(R22), -N(R20)-C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; n said C1_6 alkyl or heterocyclyl is optionally tuted with one, two or three substituents independently selected from the group consisting of halo, oxo, heteroaryl and -O-R20; R20 and R22 are in each instance ndently selected from the group consisting of hydrogen, C1_6 alkyl, lkyl, heterocyclyl, aryl and heteroaryl; and wherein the C1_6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents ndently selected from the group consisting of hydroxyl, halo, C1_4 alkyl, acylamino, oxo, NO; 6021126, -CN, C1_3 alkoxy, aryloxy, -CF3, -OCF3, -OCH2CF3, -C(O)-NH2, aryl, cycloalkyl and heteroaryl; wherein said heteroaryl is optionally fiarther substituted with C1_4 alkyl or cycloalkyl; or when R20 and R22 are attached to a common nitrogen atom R20 and R22 may join to form a heterocyclyl or heteroaryl which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C1_4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -N02, -SOZR26, -CN, C1_3 alkoxy, -CF3, -OCF3, aryl, heteroaryl and cycloalkyl; each R26 is independently selected from the group consisting of hydrogen, C1_4 alkyl, aryl and cycloalkyl; and wherein the C1_4 alkyl, aryl and cycloalkyl may be fiarther substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C1_4 alkoxy, -CF3 and -OCF3; WO 06463 or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof; provided that when R2 and R4 join er with the atom to which they are attached to form an optionally tuted imidazolyl, the imidazolyl it is not directly substituted with an optionally substituted triazolyl, or R1 is not optionally tuted pyrazolyl, 2-pyridinonyl or opyridinyl.
Some embodiments provide a method of using the compounds of Formula I, IA, IE or VII, or additional Formula(s) described throughout, in the treatment of a disease or condition in a mammal that is amenable to treatment by a late sodium channel blocker.
Such es include cardiovascular diseases such as atrial and cular arrhythmias, lO heart failure (including tive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal’s (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, usion injury, myocardial infarction, acute coronary syndrome, peripheral arterial e and intermittent claudication. Such diseases may also e diabetes and conditions d to diabetes, e.g. diabetic eral neuropathy. Such diseases may also include conditions affecting the neuromuscular system resulting in pain, seizures or paralysis. ore, it is contemplated that the compounds of the disclosure and their pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers and/or tautomer forms are potentially of use as medicaments for the treatment of the aforementioned diseases.
In certain embodiments, the disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of the disclosure (e. g. a compound of Formula I, IA, IE or VII or additional Formulas described throughout), and at least one pharmaceutically able excipient.
[0008] In certain embodiments, the compound is: 3-cyclopropyl- l 0-(4-(trifluoromethyl)phenyl)-5 ,6- dihydrobenzo[f] [ l ,2,4]triazolo[4,3-d] [ l ,4]oxazepine 3-methyl- l 0-(4-(trifluoromethyl)phenyl)-5 ,6-dihydrobenzo [f]imidazo[ l ,2- d] [ l ,4]oxazepine 3-(pyrimidinyl)— l 0-(4-(trifluoromethyl)phenyl)-5 ,6-dihydrobenzo [f]imidazo[ l ,2- d] [ l ,4]oxazepine 3-cyclopropyl(4-(trifluorornethoxy)phenyl)—5 ,6-dihydrobenzo[flimidazo[ 1 ,2- 1-18 d][1,4]0xazepine 11-1 5 -rn0rpholino(4-(trifluorornethyl)phenyl)—2,3-dihydr0benzo [f] [ 1 zepine 11-2 N—benzyl(4-(trifluoromethyl)phenyl)-2,3-dihydr0benzo [f] [ 1 ,4]oxazepinamine -(pyrrolidiny1)(4-(trifluorornethyl)phenyl)—2,3 - 11-3 dihydrobenzo[f][1 ,4]0xazepine N—cyclopropyl(4-(trifluoromethyl)phenyl)—2,3-dihydr0benz0[f][1,4]oxazepin-5 - 11-4 amine N—benzyl-N—rnethyl(4-(trifluorornethyl)phenyl)-2,3 - 11-5 dihydrobenzo[f][1 ,4]oxazepinamine N—((3-fluor0pyridin-Z-yl)rnethy1)—7-(4-(trifluoromethyl)phenyl)—2,3- 11-9 dihydrobenzo[f][1 ,4]oxazepinamine N—(pyridinylrnethyl)(4-(trifluor0rnethyl)phenyl)-2 3 - 11-10 , dihydrobenzo[f][1 ,4]oxazepinamine N—(cyclopropylmethyl)—7-(4-(trifluorornethyl)phenyl)—2,3 - 11-11 dihydrobenzo[f][1 ,4]oxazepinamine (S)—tert-butyl 1-(7-(4-(trifluoromethyl)phenyl)—2,3 r0benz0[f][1 ,4]oxazepin-5 - 11-13 y1)pyrr01idin-3 -ylcarbarnate N—(2-(1H-irnidazoly1)ethy1)(4-(trifluorornethyl)phenyl)-2,3 - 11-14 dihydrobenzo[f][1 ,4]oxazepinamine (S)—N,N—dimethyl(7-(4-(trifluorornethyl)phenyl)-2,3 - 11-15 dihydrobenzo [f] [ 1 ,4]oxazepin-5 -y1)pyrrolidin-3 e N—(pyridin-Z-yl)(4-(trifluorornethyl)phenyl)—2,3 -dihydr0benz0[f][1 ,4]oxazepin- 11-19 -amine N—(2-(pyridin-Z-yloxy)ethyl)(4-(trifluoromethyl)phenyl)—2,3- 11-20 dihydrobenzo[f][1 ,4]oxazepinamine N—(2-phen0xyethy1)—7-(4-(trifluoromethyl)phenyl)-2,3 - 11-22 dihydrobenzo[f][1 ,4]oxazepinamine 2-ch10rophenoxy)ethyl)(4-(trifluorornethyl)phenyl)-2,3- 11-24 dihydrobenzo[f][1 ,4]oxazepinamine 7-(4-(trifluorornethyl)phenyl)—N—((6-(trifluoromethyl)pyridin-Z-y1)rnethyl)-2 ,3 - 11-25 obenzo[f][1 ,4]oxazepinamine -(4-cyclopr0pylpiperaziny1)(4-(trifluor0rnethyl)phenyl)-2,3 - 11-31 dihydrobenzo[f][1 ,4]0xazepine WO 06463 11-32 N—phenyl(4-(trifluorornethyl)phenyl)-2,3-dihydr0benzo [f] [ 1 ,4]oxazepinamine N—((1 -rnethy1— 1H-benzo[d]imidazo1y1)rnethyl)(4-(trifluorornethyl)phenyl)—2,3 - 11-33 dihydrobenzo[f][1 ,4]oxazepinamine imidin-Z-ylmethyl)(7-(4-(trifluoromethyl)phenyl)-2,3 - 11-37 obenzo [f] [ 1 ,4]oxazepin-5 -y1)pyrrolidin-3 -arnine (R)-tert-butyl methyl( 1 -(7-(4-(trifluorornethyl)phenyl)—2,3 - 11-38 dihydrobenzo [f] [ 1 ,4]OXazepin-S-y1)pyrr01idin-3 -y1)carbamate (R)-N-rnethy1—1 -(7-(4-(trifluoromethyl)phenyl)-2,3-dihydr0benzo [f] [ 1 ,4]oxazepin- 11-39 -y1)pyrrolidinamine (S)-tert-butyl methy1(1-(7-(4-(triflu0r0rnethyl)phenyl)-2,3- 11-40 dihydrobenzo [f] [ 1 ,4]oxazepin-S-yl)pyrrolidin-3 -y1)carbamate (S)—tert-butyl 3 -(7-(4-(trifluorornethyl)phenyl)—2,3 -dihydr0benz0[f][1 ,4]oxazepin-5 - 11-43 ylarnino)pyrrolidine- 1 xylate (R)-N-(1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydr0benzo[f][1,4]oxazepin 11-47 yl)pyrr01idiny1)picolinarnide (S)—N,N—diethyl(7-(4-(triflu0romethyl)phenyl)-2,3 - 11-48 dihydrobenzo [f] [ 1 ,4]oxazepin-5 -y1)pyrrolidin-3 -arnine (R)-tert-butyl 1-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]0xazepin 11-50 y1)pyrr01idinylcarbarnate (R)-N,N—dirnethyl(7-(4-(triflu0romethyl)phenyl)-2,3 - 11-51 dihydrobenzo [f] [ 1 ,4]oxazepin-5 -y1)pyrrolidin-3 -arnine 11-54 N—phenyl(4-(trifluorornethyl)phenyl)-2,3-dihydr0benzo [f] [ 1 ,4]oxazepinamine -(3 -m0rph01inopyrrolidin(4-(triflu0r0rnethyl)phenyl)-2,3- 11-55 dihydrobenzo[f][1 zepine (S)(7-(4-(trifluoromethyl)phenyl)—2,3-dihydr0benzo[f][1,4]oxazepin 11-56 yl)pyrrolidinarnine tert-butyl 1 -(7-(4-(trifluorornethyl)pheny1)—2,3-dihydrobenz0[f] [ 1 ,4]oxazepin-5 - 11-57 y1)pyrr01idinylcarbarnate -(2-(pyridinyl)pyrrolidiny1)(4-(trifluorornethyl)pheny1)-2,3 - 11-58 dihydrobenzo[f][1 ,4]0xazepine -(3-(pyridinyl)pyrrolidiny1)(4-(trifluorornethyl)phenyl)-2,3- 11-60 dihydrobenzo[f][1 ,4]0xazepine 1-(naphthalen-1 -y10xy)—3 -((R)-1 -(7-(4-(triflu0r0rnethyl)phenyl)-2 ,3 - 11-61 dihydrobenzo [f] [ 1 ,4]OXazepin-S rrolidin-3 -y1arnino)pr0pan01 1001357339 tert—butyl 3 -(7—(4—(trifluoromethyl)phenyl)-2,3—dihydrobenzo [f] [1 ,4]oxazepin-5 — 11—62 ylamino)pyrrolidine- l -carboxylate (R)-tert—butyl 3 -(7—(4—(trifluoromethyl)phenyl)~2,3 -dihydrobenzo[t] [1 ,4]oxazepin-5 - 11-63 ylamino)pyrrolidine— l xylate or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or er thereof.
The inventions of this disclosure are described hout. In addition, specific embodiments of the invention are as disclosed herein.
Detailed Description 1. Definitions and l Parameters nce to any prior art in the specification is not an acknowledgment or suggestion that this prior art forms part of the common general knowledge in any jurisdiction or that this prior art could reasonably be expected to be understood, regarded as relevant, and/or combined with other pieces of prior art by a person skilled in the art. [0010a] As used in the present specification, the following words and phrases are generally intended to have the gs as set forth below, except to the extent that the context in which they are used indicates otherwise. [0010b] As used herein, except where the t requires otherwise the term ‘comprise’ and ions of the term, such as ‘comprising’, “comprises’ and ‘Comprised’, are not intended to exclude other additives, components, integers or steps.
The term "alkyl" refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 20 carbon atoms, or from 1 to 15 carbon atoms, or from 1 to 10 carbon atoms, or from 1 to 8 carbon atoms, or from 1 to 6 carbon atoms, or from 1 to 4 carbon atoms.
This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-hexyl, n-deeyl, tetradecyl, and the like. 1001357339 The term "substituted alkyl" refers to: 1) an alkyl group as defined above, having 1, 2, 3, 4 or 5 tuents, (in some embodiments, 1, 2 or 3 substituents) selected from the group ting of alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, aryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, yamino, alkoxyamino, nitro, alkyl, —S(O)—cycloalkyl, ~S(O)—heterocyclyl, — S(O)~aryl,—S(O)—heteroaryl, —S(O)2—alkyl, ~S(O)2—cycloalkyl, —S(O)2—heterocyclyl, — S(O)2—aryl and —S(O)2—heteroary1. Unless otherwise constrained by the definition, all substituents may optionally be further tuted by l, 2 or 3 tuents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, lkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2; or 2) an alkyl group as defined above that is interrupted by 1-10 atoms (e. g. l, 2, 3, 4 or 5 atoms) independently chosen from oxygen, sulfur and NRa, where Ra is chosen from hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl. All substituents may be ally further substituted by alkyl, alkenyl, alkynyl, y, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or aryl and n is 0, l or 2; or 3) an alkyl group as defined above that has both 1, 2, 3, 4 or 5 substituents as defined above and is also interrupted by 1-10 atoms (e. g. l, 2, 3, 4 or 5 atoms) as defined above.
The term “lower alkyl” refers to a monoradical branched or unbranched saturated hydrocarbon chain having 1, 2, 3, 4, 5 or 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tbutyl , n-hexyl, and the like.
[0014] The term “substituted lower alky ” refers to lower alkyl as defined above having 1 to 5 substituents (in some embodiments, l, 2 or 3 substituents), as defined for substituted alkyl or a lower alkyl group as defined above that is interrupted by l, 2, 3, 4 or atoms as defined for substituted alkyl or a lower alkyl group as defined above that has both 1, 2, 3, 4 or 5 substituents as defined above and is also interrupted by l, 2, 3, 4 or 5 atoms as defined above.
The term “alkylene” refers to a diradical of a branched or unbranched saturated hydrocarbon chain, in some embodiments, having from 1 to 20 carbon atoms (e.g. l-lO carbon atoms or 1, 2, 3, 4, 5 or 6 carbon atoms). This term is exemplified by groups such as methylene (-CH2-), ne (-CH2CH2-), the propylene isomers (e. g., -CH2CH2CH2- and -CH(CH3)CH2-), and the like.
The term “lower alkylene” refers to a diradical of a branched or unbranched saturated hydrocarbon chain, in some embodiments, having 1, 2, 3, 4, 5 or 6 carbon atoms.
The term “substituted alkylene” refers to an alkylene group as defined above having 1 to 5 substituents (in some ments, l, 2 or 3 substituents) as defined for substituted alkyl.
The term “aralkyl” refers to an aryl group covalently linked to an alkylene group, Where aryl and alkylene are defined herein. “Optionally substituted l” refers to an optionally substituted aryl group covalently linked to an optionally substituted alkylene group. Such aralkyl groups are ified by benzyl, ethyl, 3-(4- methoxyphenyl)propyl, and the like.
The term “aralkyloxy” refers to the group —O-aralkyl. “Optionally tuted aralkyloxy” refers to an optionally substituted aralkyl group covalently linked to an optionally substituted alkylene group. Such aralkyl groups are exemplified by benzyloxy, phenylethyloxy, and the like.
The term “alkenyl” refers to a dical of a branched or unbranched unsaturated hydrocarbon group haVing from 2 to 20 carbon atoms (in some embodiments, from 2 to 10 carbon atoms, e. g. 2 to 6 carbon atoms) and haVing from 1 to 6 carbon- carbon double bonds, e. g. l, 2 or 3 carbon-carbon double bonds. In some embodiments, alkenyl groups include ethenyl (or Vinyl, i.e. 2), l-propylene (or allyl, i.e.
-CH2CH=CH2), isopropylene 3)=CH2), and the like.
The term “lower alkenyl” refers to alkenyl as defined above haVing from 2 to 6 carbon atoms.
The term “substituted alkenyl” refers to an alkenyl group as defined above having 1 to 5 substituents (in some embodiments, l, 2 or 3 substituents) as defined for substituted alkyl.
The term “alkenylene” refers to a diradical of a branched or unbranched unsaturated hydrocarbon group haVing from 2 to 20 carbon atoms (in some embodiments, from 2 to 10 carbon atoms, e. g. 2 to 6 carbon atoms) and haVing from 1 to 6 carbon- carbon double bonds, e. g. l, 2 or 3 carbon-carbon double bonds.
The term “alkynyl” refers to a dical of an unsaturated hydrocarbon, in some embodiments, having from 2 to 20 carbon atoms (in some embodiments, from 2 to carbon atoms, e. g. 2 to 6 carbon atoms) and having from I to 6 carbon-carbon triple bonds e. g. l, 2 or 3 carbon-carbon triple bonds. In some embodiments, alkynyl groups include ethynyl (-CECH), propargyl (or propynyl, i.e. -CECCH3), and the like.
The term “substituted alkynyl” refers to an alkynyl group as defined above having 1 to 5 substituents (in some embodiments, l, 2 or 3 substituents) as defined for substituted alkyl.
The term “alkynylene” refers to a diradical of an unsaturated hydrocarbon, in some embodiments, having from 2 to 20 carbon atoms (in some ments, from 2 to carbon atoms, e. g. 2 to 6 carbon atoms) and having from I to 6 carbon-carbon triple bonds e.g. l, 2 or 3 carbon-carbon triple bonds.
The term “hydroxy” or “hydroxyl” refers to a group —OH.
The term “alkoxy” refers to the group R-O-, where R is alkyl or -Y-Z, in which Y is alkylene and Z is alkenyl or alkynyl, where alkyl, alkenyl and alkynyl are as defined herein. In some embodiments, alkoxy groups are alkyl-O- and includes, by way of e, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert—butoxy, sec-butoxy, n- pentoxy, n-hexyloxy, l,2-dimethylbutoxy, and the like.
The term “lower ” refers to the group R-O- in which R is optionally tuted lower alkyl. This term is exemplified by groups such as methoxy, , n- propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, n-hexyloxy, and the like.
The term “substituted alkoxy” refers to the group R-O-, where R is substituted alkyl or -Y-Z, in which Y is tuted alkylene and Z is substituted alkenyl or substituted alkynyl, where tuted alkyl, substituted alkenyl and substituted alkynyl are as defined herein.
The term “C1_3 haloalkyl” refers to an alkyl group having from I to 3 carbon atoms covalently bonded to from I to 7, or from I to 6, or from I to 3, halogen(s), where alkyl and halogen are defined . In some embodiments, C1_3 haloalkyl includes, by way of example, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoroethyl, 2,2- difluoroethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, 3,3-difluoropropyl, 3-fluoropropyl.
The term “cycloalkyl” refers to cyclic alkyl groups of from 3 to 20 carbon atoms, or from 3 to 10 carbon atoms, having a single cyclic ring or multiple condensed rings. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl and the like or multiple ring structures such as adamantanyl and bicyclo[2.2. l]heptanyl or cyclic alkyl groups to which is fused an aryl group, for example indanyl, and the like, provided that the point of attachment is through the cyclic alkyl group.
The term “cycloalkenyl” refers to cyclic alkyl groups of from 3 to 20 carbon atoms haVing a single cyclic ring or le condensed rings and haVing at least one double bond and in some embodiments, from 1 to 2 double bonds.
The terms “substituted cycloalkyl” and “susbstituted cycloalkenyl” refer to cycloalkyl or lkenyl groups having 1, 2, 3, 4 or 5 substituents (in some embodiments, l, 2 or 3 substituents), selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, lkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, y, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, amino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, aryl,-S(O)- heteroaryl, -alkyl, -S(O)2-cycloalkyl, -S(O)2-heterocyclyl, -S(O)2-aryl and -S(O)2- heteroaryl. The term “substituted cycloalkyl” also includes cycloalkyl groups wherein one or more of the annular carbon atoms of the cycloalkyl group has an oxo group bonded thereto. In addition, a substituent on the cycloalkyl or cycloalkenyl may be ed to the same carbon atom as, or is l to, the attachment of the substituted cycloalkyl or cycloalkenyl to the 6,7-ring system. Unless otherwise constrained by the definition, all substituents may ally be further substituted by l, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, arbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2.
[0035] The term “cycloalkoxy” refers to the group cycloalkyl-O-.
The term “substituted cycloalkoxy” refers to the group substituted cycloalkyl-O-.
The term “cycloalkenyloxy” refers to the group cycloalkenyl-O-.
The term “substituted lkenyloxy” refers to the group substituted cycloalkenyl-O-.
The term “aryl” refers to an aromatic carbocyclic group of 6 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple rings (e.g., biphenyl) or multiple condensed (filsed) rings (e.g., naphthyl, fluorenyl and anthryl). In some embodiments, aryls include phenyl, fluorenyl, naphthyl, anthryl, and the like.
Unless otherwise ained by the definition for the aryl substituent, such aryl groups can ally be substituted with l, 2, 3, 4 or 5 tuents (in some embodiments, l, 2 or 3 substituents), selected fiom the group consisting of alkyl, alkenyl, alkynyl, , cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, aryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)—aryl,-S(O)- heteroaryl, -S(O)2-alkyl, -cycloalkyl, -S(O)2-heterocyclyl, -S(O)2-aryl and -S(O)2- heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be fiarther substituted by l, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, n, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or aryl and n is 0, l or 2.
The term “aryloxy” refers to the group aryl-O- wherein the aryl group is as defined above, and includes optionally substituted aryl groups as also defined above. The term “arylthio” refers to the group R-S-, where R is as defined for aryl.
[0042] The term “heterocyclyl,” “heterocycle,” or “heterocyclic” refers to a monoradical saturated group haVing a single ring or multiple sed rings, haVing from 1 to 40 carbon atoms and from 1 to 10 hetero atoms, and from 1 to 4 heteroatoms, selected from nitrogen, sulfur, phosphorus, and/or oxygen within the ring. In some embodiments, the heterocyclyl,” “heterocycle,” or “heterocyclic” group is linked to the remainder of the molecule through one of the heteroatoms within the ring.
Unless ise constrained by the definition for the heterocyclic substituent, such heterocyclic groups can be optionally substituted with l to 5 substituents (in some embodiments, l, 2 or 3 substituents), selected from the group consisting of alkyl, alkenyl, l, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, carbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, yamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, heterocyclyl, -S(O)—aryl,-S(O)- heteroaryl, -S(O)2-alkyl, -S(O)2-cycloalkyl, -S(O)2-heterocyclyl, -S(O)2-aryl and -S(O)2- heteroaryl. In addition, a substituent on the heterocyclic group may be ed to the same carbon atom as, or is geminal to, the attachment of the substituted heterocyclic group to the 6,7-ring system. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by l, 2 or 3 substituents chosen from alkyl, l, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, lkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2. Examples of heterocyclics e tetrahydrofuranyl, morpholino, piperidinyl, and the like.
The term “heterocyclooxy” refers to the group —O-heterocyclyl.
The term “heteroaryl” refers to a group comprising single or multiple rings comprising 1 to 15 carbon atoms and l to 4 heteroatoms selected from oxygen, nitrogen and sulfur within at least one ring. The term “heteroaryl” is generic to the terms “aromatic heteroaryl” and “partially ted heteroaryl”. The term tic heteroaryl” refers to a heteroaryl in which at least one ring is aromatic, regardless of the point of attachment. Examples of aromatic heteroaryls include pyrrole, thiophene, pyridine, quinoline, ine.
[0046] The term “partially saturated heteroaryl” refers to a heteroaryl haVing a structure lent to an ying aromatic heteroaryl which has had one or more double bonds in an aromatic ring of the underlying aromatic heteroaryl saturated. Examples of partially saturated heteroaryls include dihydropyrrole, dihydropyridine, chroman, 2-oxo-l,2- dihydropyridinyl, and the like.
[0047] Unless otherwise constrained by the definition for the heteroaryl substituent, such heteroaryl groups can be optionally substituted with l to 5 substituents (in some ments, l, 2 or 3 tuents) selected from the group consisting alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, y, amino, tuted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, io, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)—aryl,-S(O)- heteroaryl, -alkyl, -S(O)2-cycloalkyl, -S(O)2-heterocyclyl, -S(O)2-aryl and -S(O)2- heteroaryl. Unless otherwise ained by the definition, all substituents may optionally be fiarther substituted by l, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2. Such heteroaryl groups can have a single ring (e.g., pyridyl or fiaryl) or multiple condensed rings (e.g., indolizinyl, benzothiazole or benzothienyl). Examples of nitrogen heterocyclyls and heteroaryls include, but are not limited to, pyrrole, ole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, and the like as well as xy- nitrogen containing heteroaryl compounds.
The term oaryloxy” refers to the group aryl-O-.
The term “amino” refers to the group -NH2.
The term “substituted amino” refers to the group -NRR where each R is independently ed from the group consisting of hydrogen, alkyl, lkyl, aryl, aryl and heterocyclyl provided that both R groups are not en or a group -Y- Z, in which Y is optionally substituted alkylene and Z is alkenyl, cycloalkenyl or alkynyl.
Unless otherwise constrained by the definition, all substituents may ally be further substituted by l, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2.
The term “alkyl amine” refers to R-NH2 in which R is optionally substituted alkyl.
The term yl amine” refers to R-NHR in which each R is independently an optionally tuted alkyl.
The term “trialkyl amine” refers to NR3 in which each R is independently an optionally substituted alkyl.
The term “cyano” refers to the group -CN.
The term “azido” refers to a group —N=N=N .
The term “keto” or “oxo” refers to a group =0.
[0057] The term “carboxy” refers to a group -C(O)-OH.
The term “ester” or “carboxyester” refers to the group -C(O)OR, where R is alkyl, lkyl, aryl, heteroaryl or heterocyclyl, which may be optionally fiarther tuted by alkyl, alkoxy, halogen, CF3, amino, substituted amino, cyano or —S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2.
[0059] The term “acyl” denotes the group -C(O)R, in which R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be filrther substituted by l, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2.
The term “carboxyalkyl” refers to the groups -C(O)O-alkyl or - cycloalkyl, where alkyl and lkyl are as defined herein, and may be optionally fiarther substituted by alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, y, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2.
The term “aminocarbonyl” refers to the group -C(O)NRR where each R is ndently hydrogen, alkyl, cycloalkyl, aryl, aryl, or heterocyclyl, or where both R groups are joined to form a cyclic group (e.g., morpholino). Unless otherwise constrained by the definition, all substituents may optionally be further substituted by l, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and Ra, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2.
The term “acyloxy” refers to the group —OC(O)—R, in which R is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. Unless otherwise ained by the ion, all substituents may ally be r substituted by l, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, , halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2.
The term “acylamino” refers to the group -NRC(O)R where each R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl. Unless otherwise constrained by the definition, all tuents may optionally be further substituted by l, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2.
The term “alkoxycarbonylamino” refers to the group C(O)OR in which R is alkyl and RC1 is hydrogen or alkyl. Unless otherwise constrained by the definition, each alkyl may optionally be further substituted by l, 2 or 3 substituents ed from the group consisting of alkyl, alkenyl, l, carboxy, carboxyalkyl, arbonyl, hydroxy, , halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2.
[0065] The term “aminocarbonylamino” refers to the group —NR°C(O)NRR, wherein R0 is hydrogen or alkyl and each R is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl. Unless ise constrained by the definition, all substituents may optionally be further substituted by l, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2.
The term “thiol” refers to the group -SH.
The term “thiocarbonyl” refers to a group =S.
The term “alkylthio” refers to the group -S-alkyl.
The term “substituted alkylthio” refers to the group —S-substituted alkyl.
The term “heterocyclylthio” refers to the group —S-heterocyclyl.
The term “arylthio” refers to the group —S-aryl.
The term “heteroarylthiol” refers to the group —S-heteroaryl wherein the heteroaryl group is as defined above including optionally substituted heteroaryl groups as also defined above.
The term xide” refers to a group -S(O)R, in which R is alkyl, lkyl, heterocyclyl, aryl or heteroaryl. ituted sulfoxide” refers to a group -S(O)R, in which R is tuted alkyl, substituted cycloalkyl, tuted heterocyclyl, substituted aryl or substituted heteroaryl, as defined herein.
The term “sulfone” refers to a group -S(O)2R, in which R is alkyl, cycloalkyl, cyclyl, aryl or heteroaryl. “Substituted sulfone” refers to a group R, in which R is substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted aryl or substituted heteroaryl, as defined herein.
The term “aminosulfonyl” refers to the group —S(O)2NRR, wherein each R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by l, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, n, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)nRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, l or 2.
The term xyamino” refers to the group —NHOH.
[0077] The term “alkoxyamino” refers to the group —NHOR in which R is optionally substituted alkyl.
The term “halogen” or “halo” refers to fluoro, bromo, chloro and iodo.
“Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. 2012/045021 A “substituted” group includes embodiments in which a monoradical substituent is bound to a single atom of the substituted group (e. g. forming a branch), and also includes embodiments in which the tuent may be a diradical bridging group bound to two adjacent atoms of the substituted group, thereby forming a fused ring on the substituted group.
Where a given group (moiety) is described herein as being ed to a second group and the site of attachment is not explicit, the given group may be ed at any available site of the given group to any available site of the second group. For example, a “lower alkyl-substituted ”, where the attachment sites are not explicit, may have any available site of the lower alkyl group attached to any available site of the phenyl group. In this regard, an able site” is a site of the group at which a hydrogen of the group may be replaced with a substituent.
It is understood that in all substituted groups defined above, polymers arrived at by defining tuents with fiarther substituents to themselves (e.g., substituted aryl having a substituted aryl group as a substituent which is itself substituted with a tuted aryl group, etc.) are not ed for inclusion herein. Also not included are infinite numbers of substituents, whether the substituents are the same or different. In such cases, the maximum number of such substituents is three. Each of the above definitions is thus constrained by a limitation that, for example, substituted aryl groups are limited to -substituted aryl-(substituted aryl)-substituted aryl.
A compound of a given formula (e. g. the nd of Formula I, which also includes Formula IA, IB and/or VII) is ed to encompass the compounds of the disclosure, and the pharmaceutically acceptable salts, stereoisomers, mixture of stereoisomers or tautomers of such compounds. Additionally, the compounds of the disclosure may possess one or more asymmetric centers, and can be produced as a racemic mixture or as individual omers or diastereoisomers. The number of stereoisomers present in any given compound of a given formula depends upon the number of asymmetric centers present (there are 211 stereoisomers possible where n is the number of asymmetric centers). The individual stereoisomers may be obtained by resolving a racemic or cemic mixture of an intermediate at some appropriate stage of the synthesis or by resolution of the compound by conventional means. The individual stereoisomers (including individual enantiomers and diastereoisomers) as well as racemic and non-racemic mixtures of stereoisomers are encompassed within the scope of the present disclosure, all of which are ed to be depicted by the ures of this cation unless otherwise specifically indicated.
“Isomers” are different compounds that have the same molecular formula.
Isomers include stereoisomers, enantiomers and diastereomers.
“Stereoisomers” are isomers that differ only in the way the atoms are arranged in space.
“Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term "(::)" is used to ate a racemic mixture where riate.
[0087] “Diastereoisomers” are stereoisomers that have at least two tric atoms, but which are not mirror-images of each other.
The absolute stereochemistry is specified according to the Cahn Ingold Prelog R S system. When the compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown are designated (+) or (-) depending on the ion (dextro- or laevorotary) that they rotate the plane of polarized light at the wavelength of the sodium D line.
Some of the compounds exist as tautomeric isomers. Tautomeric isomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. se, the imidic acid containing compounds are understood to include their amide ers. Non-limiting examples of tautomers are shown below: / / N HN NH \N o) o), The term “therapeutically effective amount” refers to an amount that is sufficient to effect ent, as defined below, when administered to a mammal in need of such 2012/045021 treatment. The therapeutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the e condition, the manner of administration and the like, which can y be determined by one of ry skill in the art.
The term “polymorph” refers to different crystal structures of a crystalline compound. The different polymorphs may result from differences in crystal g (packing polymorphism) or differences in packing between different conformers of the same molecule (conformational polymorphism).
The term “solvate” refers to a complex formed by the combining of a compound of Formula I, IA, IE or VII and a solvent.
The term “hydrate” refers to the complex formed by the combining of a compound of Formula 1, IA, 1B or VII and water.
The term ug” refers to compounds of Formula 1, IA, 1B or VII that include chemical groups which, in viva, can be converted and/or can be split off from the remainder of the le to provide for the active drug, a pharmaceutically acceptable salt thereof or a biologically active lite thereof.
Any a or structure given herein, including Formula I, IA, IE or VII compounds, is also intended to represent unlabeled forms as well as isotopically labeled forms of the nds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to 2H (deuterium, D), 3H (tritium), 11C, 13C, 14C, 15N, 18F, 31F, 32F, 358, 36Cl and 125I. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as 3H, 13 C and 14C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission aphy (PET) or single-photon emission computed tomography (SPECT) ing drug or ate tissue distribution assays or in radioactive treatment of patients.
The disclosure also included compounds of Formula I, IA, IB or VII in which from 1 to n hydrogens attached to a carbon atom is/are replaced by ium, in which n is the number of hydrogens in the molecule. Such compounds exhibit increased ance to metabolism and are thus useful for increasing the half life of any compound of Formula I, IA, IE or VII when administered to a mammal. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism”, Trends Pharmacol. Sci. 524-527 (1984). Such compounds are synthesized by means well known in the art, for example by ing starting materials in which one or more hydrogens have been replaced by deuterium.
[0097] Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug lism and pharmacokinetics) properties, ng to distribution, lism and excretion (ADME). Substitution with r isotopes such as ium may afford certain therapeutic advantages resulting from greater lic stability, for example increased in viva half-life, reduced dosage requirements and/or an improvement in eutic index. An 18F labeled compound may be useful for PET or SPECT studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is tood that deuterium in this context is regarded as a substituent in the compound of Formula I, IA, IE or VII.
The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this sure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as "H" or "hydrogen", the position is understood to have hydrogen at its natural nce isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium.
The term “treatment” or “treating” means administration of a nd of the invention, by or at the direction of a competent caregiver, to a mammal having a disease for purposes including: (i) preventing the disease, that is, causing the clinical symptoms of the disease not to develop; (ii) inhibiting the disease, that is, arresting the development of clinical symptoms; and/or (iii) relieving the disease, that is, causing the sion of clinical ms.
In many cases, the compounds of this disclosure are e of forming acid and/or base salts by Virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
The term “pharmaceutically acceptable salt” of a given compound refers to salts that retain the ical effectiveness and ties of the given compound, and which are not biologically or otherwise undesirable. Pharmaceutically acceptable base addition salts can be prepared from nic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts d from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl , substituted alkyl amines, di(substituted alkyl) , tri(substituted alkyl) amines, alkenyl , dialkenyl amines, trialkenyl amines, substituted alkenyl amines, stituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, tuted cycloalkyl amines, disubstituted cycloalkyl amine, trisubstituted cycloalkyl amines, cycloalkenyl , loalkenyl) amines, tri(cycloalkenyl) amines, substituted cycloalkenyl amines, tituted cycloalkenyl amine, trisubstituted cycloalkenyl amines, aryl amines, diaryl amines, triaryl amines, heteroaryl amines, diheteroaryl amines, triheteroaryl amines, heterocyclic amines, diheterocyclic amines, triheterocyclic amines, mixed di- and tri-amines where at least two of the substituents on the amine are different and are selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, and the like. Also included are amines where the two or three substituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group. Amines are of general ure N(R30)(R31)(R32), wherein mono-substituted amines have 2 of the three substituents on nitrogen (R30, R31 and R32)as hydrogen, di-substituted amines have 1 of the three substituents on nitrogen R30, R31 and R32 as h droy gen, whereas tri-substituted amines have none of the three substituents on nitrogen (R30, R31 and R32) as hydrogen. R30, R31 and R32 are selected from a variety of substituents such as hydrogen, optionally substituted alkyl, aryl, heteroayl, lkyl, cycloalkenyl, heterocyclyl and the like. The above-mentioned amines refer to the compounds n either one, two or three tuents on the nitrogen are as listed in the name. For example, the term alkenyl amine” refers to cycloalkenyl-NH2, n “cycloalkeny ” is as defined herein. The term “diheteroarylamine” refers to eroaryl)2, wherein “heteroaryl” is as defined herein and so on.
Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, ne, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N- lucamines, theobromine, purines, piperazine, piperidine, morpholine, N- ethylpiperidine, and the like.
[0103] Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, ic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
As used herein, “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and ngal agents, isotonic and absorption delaying agents and the like.
The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic itions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
“Coronary diseases” or “cardiovascular diseases” refer to diseases of the cardiovasculature arising from any one or more than one of, for example, heart e (including congestive heart failure, diastolic heart failure and ic heart failure), acute heart failure, ischemia, recurrent ischemia, myocardial tion, arrhythmias, angina (including exercise-induced , t , stable angina, unstable angina), acute coronary syndrome, diabetes and intermittent claudication.
“Intermittent claudication” means the pain associated with peripheral artery disease. “Peripheral artery disease” or PAD is a type of occlusive peripheral vascular disease (PVD). PAD s the arteries outside the heart and brain. The most common symptom ofPAD is a painful cramping in the hips, thighs or calves when g, climbing stairs or sing. The pain is called ittent claudication. When listing the symptom intermittent claudication, it is intended to include both PAD and PVD.
Arrhythmia refers to any abnormal heart rate. Bradycardia refers to abnormally slow heart rate whereas tachycardia refers to an abnormally rapid heart rate. As used herein, the treatment of arrhythmia is intended to include the treatment of supra ventricular tachycardias such as atrial fibrillation, atrial flutter, AV nodal reentrant ardia, atrial tachycardia and the ventricular tachycardias (VTs), including thic ventricular tachycardia, ventricular fibrillation, pre-excitation syndrome and Torsade de Pointes (TdP). 2. Nomenclature Names of compounds of the present disclosure are provided using ACD/Name software for naming chemical compounds (Advanced Chemistry Development, Inc., Toronto). Other compounds or radicals may be named with common names or systematic or non-systematic names. The naming and ing of the compounds of the disclosure is illustrated with a representative compound of Formula I: F 2 9 J5 8 O 6 which is named l0-(4-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f]imidazo[l,2- d] [ l ,4]oxazepine. 3. Compounds Accordingly, typical embodiments the present disclosure provide novel compounds that function as late sodium channel blockers. In one ment, the disclosure provides compounds of Formula I: R1€sz>' / 04\(R3>n wherein: -Y-Z- is -C(=NR4)-NR2- or -C(NR5R6)=N-; R1 is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; wherein said aryl, lkyl, cycloalkenyl, heterocyclyl or heteroaryl are ally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, -CN, -SF5, -Si(CH3)3, -O-R20, -S-R20, -C(O)—R20, -C(O)-OR20, -N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-C(O)-OR22, -N(R20)-S(=O)2-R26, -S(=O)2-R20, -O-S(=O)2-R20, -S(=O)2-N(R20)(R22), c1.6 alkyl, c2.4 alkenyl, c2.4 alkynyl, cycloalkyl, aryl, aryl and heterocyclyl; and wherein said C1_6 alkyl, C2_4 alkenyl, C2_4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents ndently selected from the group consisting of halo, -N02, phenyl, heterocyclyl, heteroaryl, C1_6 alkyl, cycloalkyl, -N(R20)(R22), -C(O)-R20, -C(O)—OR20, -C(O)- N(R20)(R22), -CN and -O-R20; R2 is hydrogen, C1_6 alkyl, -C(O)-R20, -C(O)—OR26, -C(O)-N(R26)(R26), -N(R20)-S(=O)2-R20, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, aryl or heterocyclyl are optionally tuted with one, two or three substituents independently ed from the group ting of C1_6 alkyl, C2_4 alkynyl, halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN, oxo and on”; n said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, aryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are ally fiarther tuted with one, two or three tuents independently selected from the group consisting of halo, -N02, -CF3, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN, -S(O)2-R20 and —0— R20; nisO, l,2,3or4; each R3 is independently C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and -O-R20; wherein said lkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, lkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, lkyl, aryl, heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, )(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and —0— R20; or two R3 attached to a common carbon atom form an oxo; or two R3 attached to a common or adjacent carbon atoms form a cycloalkyl or heterocyclyl; wherein said cycloalkyl or cyclyl are optionally filrther substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)—R20, -C(O)—OR20, -C(O)—N(R20)(R22), -CN and ; R4 is C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently ed from the group consisting of halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, OR20, -C(O)— (R22), -CN and -O-R20; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three tuents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, cyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally fiarther substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and ; or R2 and R4 can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group ting of halo, C1_6 alkyl, cycloalkyl, heteroaryl, -CN, -O-R20, -N(R20)(R22), -C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; and WO 06463 wherein said C1_6 alkyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -CN, -O-R20, C1_6 alkyl, aryl, and heteroaryl; R5 is hydrogen, C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)— N(R20)(R22), -CN and -O-R20; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents ndently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, )(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally fiarther substituted with one, two or three substituents independently selected from the group ting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R20, OR20; R6 is C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group ting of halo, -N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), R20, -C(O)-OR20, -C(O)— N(R20)(R22), -CN and -O-R20; wherein said C1_6 alkyl, cycloalkyl, aryl, cyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, l, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally fiarther tuted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20; or R5 and R6 can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently ed from the group consisting of halo, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, R20, -N(R20)(R22), -N(R20)-C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; wherein said C1_6 alkyl or heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, heteroaryl and -O-R20; R20 and R22 are in each instance independently ed from the group consisting of hydrogen, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl and aryl; and wherein the C1_6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group ting of hydroxyl, halo, C1_4 alkyl, acylamino, oxo, NO; 6021126, -CN, C1_3 alkoxy, aryloxy, -CF3, -OCF3, -OCH2CF3, -C(O)-NH2, aryl, cycloalkyl and heteroaryl; wherein said aryl is optionally fiarther substituted with C1_4 alkyl or cycloalkyl; or when R20 and R22 are attached to a common en atom R20 and R22 may join to form a heterocyclyl or heteroaryl which is then optionally tuted with one, two or three substituents independently ed from the group consisting of hydroxyl, halo, C1_4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -N02, -SOZR26, -CN, C1_3 alkoxy, -CF3, -OCF3, aryl, heteroaryl and cycloalkyl; and each R26 is independently selected from the group consisting of hydrogen, C1_4 alkyl, aryl and cycloalkyl; wherein the C1_4 alkyl, aryl and cycloalkyl may be r substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C1_4 alkoxy, -CF3 and -OCF3; or a pharmaceutically acceptable salt, stereoisomer, mixture of isomers, or tautomer thereof; provided that when R2 and R4 join together with the atom to which they are attached to form an optionally substituted imidazolyl, the olyl it is not directly substituted with an optionally substituted triazolyl, or R1 is not optionally substituted pyrazolyl, 2-pyridinonyl or 2-fluoropyridinyl.
In certain ments, the compound of Formula I is ented by Formula R‘—l wherein: R1 is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or aryl; n said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, -CN, -SF5, -Si(CH3)3, -O-R20, -S-R20, -C(O)—R20, -C(O)-OR20, -N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-C(O)-OR22, -N(R20)-S(=O)2-R26, -S(=O)2-R20, O)2-R20, -S(=O)2-N(R20)(R22), c1.6 alkyl, c2.4 alkenyl, c2.4 l, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1_6 alkyl, C2_4 alkenyl, C2_4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, phenyl, heterocyclyl, heteroaryl, C1_6 alkyl, cycloalkyl, -N(R20)(R22), -C(O)-R20, -C(O)—OR20, -C(O)- N(R20)(R22), -CN and -O-R20; R2 is hydrogen, C1_6 alkyl, -C(O)-R20, -C(O)—OR26, -C(O)-N(R26)(R26), -N(R20)-S(=O)2-R20, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are ally substituted with one, two or three substituents independently selected from the group consisting of C1_6 alkyl, C2_4 alkynyl, halo, -N02, cycloalkyl, aryl, heterocyclyl, aryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN, oxo and -O-R20; n said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further tuted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and ; and wherein said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally fiarther substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, -CF3, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN, -S(O)2-R20 and —0— R20_ nis 0, 1,2, 3 or4; each R3 is independently C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, lkyl, aryl, heterocyclyl, aryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and -O-R20; wherein said lkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, cyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, are optionally further tuted with one, two or three substituents independently selected from the group consisting of halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and —0— R20; or two R3 attached to a common carbon atom form an oxo; or two R3 attached to a common or adjacent carbon atoms form a cycloalkyl or heterocyclyl; wherein said cycloalkyl or heterocyclyl are optionally filrther substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, cyclyl, aryl, -N(R20)(R22), -C(O)—R20, -C(O)—OR20, -C(O)—N(R20)(R22), -CN and -O-R20; R4 is C1_6 alkyl, cycloalkyl, aryl, heteroaryl or cyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)— N(R20)(R22), -CN and -O-R20; n said cycloalkyl, aryl, heterocyclyl or heteroaryl are ally further substituted with one, two or three substituents independently selected from the group ting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and ; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally fiarther substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, N(R20)(R22), -CN and -O-R20; or R2 and R4 can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, c1.6 alkyl, cycloalkyl, heteroaryl, -CN, -O-R20, -N(R20)(R22), -C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; and wherein said C1_6 alkyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group ting of halo, -CN, -O-R20, C1_6 alkyl, aryl, and heteroaryl; R20 and R22 are in each instance independently selected from the group ting of en, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and wherein the C1_6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C1_4 alkyl, acylamino, oxo, NO; 6021126, -CN, C1_3 alkoxy, y, -CF3, -OCF3, -OCH2CF3, -C(O)-NH2, aryl, cycloalkyl and heteroaryl; wherein said heteroaryl is optionally fiarther substituted with C1_4 alkyl or cycloalkyl; or when R20 and R22 are attached to a common nitrogen atom R20 and R22 may join to form a heterocyclyl or heteroaryl which is then ally substituted with one, two or three tuents independently selected from the group consisting of hydroxyl, halo, C1_4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -N02, -SOZR26, -CN, C1_3 alkoxy, -CF3, -OCF3, aryl, heteroaryl and cycloalkyl; and each R26 is independently selected from the group consisting of hydrogen, C1_4 alkyl, aryl and cycloalkyl; wherein the C1_4 alkyl, aryl and lkyl may be fiarther substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C1_4 alkoxy, -CF3 and -OCF3; or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof; provided that when R2 and R4 join together with the atom to which they are attached to form an optionally substituted imidazolyl, the imidazolyl it is not directly substituted with an optionally substituted triazolyl, or R1 is not optionally substituted pyrazolyl, 2-pyridinonyl or 2-fluoropyridinyl.
In some embodiments, R1 is aryl; wherein said aryl is optionally substituted with one, two or three substituents independently selected from the group ting of halo, -N02, -CN, -SF5, -Si(CH3)3, -O-R20, -S-R20, -C(O)—R20, -C(O)—OR20, -N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-C(O)-OR22, -N(R20)-S(=O)2-R26, -S(=O)2-R20, -O-S(=O)2-R20, -S(=O)2-N(R20)(R22), C1_6 alkyl, C2_4 alkenyl, C2_4 l, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1_6 alkyl, C2_4 alkenyl, C2_4 l, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, , cyclyl, heteroaryl, C1_6 alkyl, cycloalkyl, -N(R20)(R22), -C(O)-R20, -C(O)—OR20, -C(O)- (R22), -CN and -O-R20.
[0112] In some embodiments, R1 is aryl optionally substituted with -O-R20 or C1_6 alkyl, n said C1_6 alkyl is optionally substituted with one, two or three halo.
In some embodiments, R1 is ary10ptionally substituted with on20 or C1_6 alkyl, wherein said C1_6 alkyl is optionally substituted with one, two or three halo.
F O In some embodiments, R1 is 2130;? 0,
[0115] In some ments, R2 and R4 'oin toJ gether with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents ndently selected from the group consisting of halo, C1_6 2012/045021 alkyl, lkyl, heteroaryl, -CN, -O-R20, -N(R20)(R22), -C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; and wherein said C1_6 alkyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -CN, -O-R20, C1_6 alkyl, aryl, and heteroaryl.
In some embodiments, R2 and R4 join together with the atom to which they are attached to form a heterocyclyl or heteroaryl selected from the group consisting of “Q ”fir fr 1% “Q’N N i;N/g Embargwfiwfiwfiw, N;OH OH 0 ELN ”‘9‘?N\ :N N\ N\ \ ,\N>’% ‘“ HLW QLN W M M Aw» N \20V QQIQ {LN ELMN \ N \ N \ N \ N’N\ ‘3‘“ / iN\ ' ' \N> ’ ‘ ’ Aw £08" w )m w /N ,N N N M \ N \ >” \ \ ’5‘” l and N‘” In some embodiments, n is 0.
In some ments, R1 is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; n said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are ally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, -CN, -SF5, -Si(CH3)3, -O-R20, -S-R20, -C(O)—R20, OR20, -N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-C(O)-OR22, -N(R20)-S(=O)2-R26, -S(=O)2-R20, -O-S(=O)2-R20, -S(=O)2-N(R20)(R22), C1_6 alkyl, c2_4 alkenyl, c2_4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1_6 alkyl, C2_4 l, C2_4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, phenyl, heterocyclyl, heteroaryl, C1_6 alkyl, cycloalkyl, )(R22), -C(O)-R20, -C(O)—OR20, -C(O)- N(R20)(R22), -CN and -O-R20; n is 0; and R2 and R4 join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, c1.6 alkyl, cycloalkyl, heteroaryl, -CN, -O-R20, -N(R20)(R22), -C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; and wherein said C1_6 alkyl or heteroaryl are optionally substituted with one, two or three tuents independently selected from the group consisting of halo, -CN, -O-R20, C1_6 alkyl, aryl, and heteroaryl.
In some embodiments, R1 is aryl; wherein said aryl is optionally substituted with one, two or three substituents independently ed from the group ting of halo, -N02, -CN, -SF5, -Si(CH3)3, -O-R20, -S-R20, -C(O)—R20, -C(O)—OR20, -N(R20)(R22), -C(O)-N(R20)(R22), )-C(O)-R22, -N(R20)-C(O)-OR22, -N(R20)-S(=O)2-R26, -S(=O)2-R20, -O-S(=O)2-R20, -S(=O)2-N(R20)(R22), C1_6 alkyl, C2_4 alkenyl, C2_4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1_6 alkyl, C2_4 alkenyl, C2_4 l, cycloalkyl, aryl, aryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, phenyl, heterocyclyl, heteroaryl, C1_6 alkyl, lkyl, -N(R20)(R22), -C(O)-R20, -C(O)—OR20, -C(O)- N(R20)(R22), -CN and -O-R20; WO 06463 2012/045021 11 is 0; and R2 and R4 join together with the atom to which they are attached to form a heterocyclyl or aryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group ting of halo, c1.6 alkyl, cycloalkyl, aryl, -CN, -O-R20, -N(R20)(R22), -C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; and wherein said C1_6 alkyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -CN, -O-R20, C1_6 alkyl, aryl, and heteroaryl.
In some embodiments, R1 is aryl optionally substituted with -O-R20 or C1_6 alkyl; wherein said C1_6 alkyl is optionally substituted with one, two or three halo; n is 0; and R2 and R4 join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, c1.6 alkyl, cycloalkyl, heteroaryl, -CN, -O-R20, -N(R20)(R22), -C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; and wherein said C1_6 alkyl or heteroaryl are optionally substituted with one, two or three substituents ndently selected from the group consisting of halo, -CN, -O-R20, C1_6 alkyl, aryl, and heteroaryl.
In some ments, R1 is phenyl substituted with -O-CF3 or -CF3; n is 0; and R2 and R4 join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, c1.6 alkyl, cycloalkyl, heteroaryl, -CN, -C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; and wherein said C1_6 alkyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -CN, -O-R20, C1_6 alkyl, aryl, and heteroaryl.
In some embodiments, the compound is selected from the group consisting of opropyl- l trifluoromethyl)phenyl)—5 ,6- dihydrobenzo[f] [ l ,2,4]triazolo[4,3-d] [ l ,4]oxazepine yl- l 0-(4-(trifluoromethyl)phenyl)—5 ydrobenzo [fjimidazo[ l ,2- d] [ l ,4]oxazepine 3-(pyrimidinyl)— l trifluoromethyl)phenyl)-5 ,6-dihydrobenzo[flimidazo[ l ,2- d] [ l ,4]oxazepine 3-cyclopropyl- l 0-(4-(trifluoromethoxy)phenyl)—5 ,6-dihydrobenzo[flimidazo[ l ,2- 1-1 8 d] [ l zepine or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.
In certain embodiments, the compound of Formula I is represented by Formula RFLN/ R1—: IB wherein: R1 is aryl, cycloalkyl, cycloalkenyl, cyclyl or heteroaryl; wherein said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are optionally substituted with one, two or three substituents ndently selected from the group consisting of halo, -N02, -CN, -SF5, -Si(CH3)3, -O-R20, -S-R20, -C(O)—R20, -C(O)-OR20, -N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-C(O)-OR22, -N(R20)-S(=O)2-R26, -S(=O)2-R20, -O-S(=O)2-R20, -S(=O)2-N(R20)(R22), C1_6 alkyl, c2_4 alkenyl, c2_4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1_6 alkyl, C2_4 alkenyl, C2_4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, phenyl, cyclyl, heteroaryl, C1_6 alkyl, cycloalkyl, -N(R20)(R22), R20, -C(O)—OR20, -C(O)- N(R20)(R22), -CN and -O-R20; nisO, 1,2, 3 or4; each R3 is independentlyC1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), R20, OR20, -C(O)-N(R20)(R22), -CN and -O-R20; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, lkyl, aryl, heterocyclyl, heteroaryl, )(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, l, cycloalkyl, aryl, heterocyclyl or heteroaryl, are optionally further tuted with one, two or three substituents independently selected from the group consisting of halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and —0— R20; or two R3 attached to a common carbon atom form an oxo; or two R3 attached to a common or adjacent carbon atoms form a lkyl or heterocyclyl; wherein said cycloalkyl or heterocyclyl are optionally filrther substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), R20, -C(O)—OR20, -C(O)—N(R20)(R22), -CN and -O-R20; R5 is hydrogen, C1_6 alkyl, lkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are ally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)— N(R20)(R22), -CN and -O-R20; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and ; and wherein said C1_6 alkyl, l, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally r substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20; R6 is C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or cyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, cycloalkyl, aryl, cyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)— N(R20)(R22), -CN and -O-R20; wherein said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), R20, -C(O)-OR20, N(R20)(R22), -CN and ; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally fiarther substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20; or R5 and R6 can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally tuted with one, two or three substituents independently selected from the group ting of halo, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, R20, -N(R20)(R22), -N(R20)-C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; wherein said C1_6 alkyl or heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, heteroaryl and -O-R20; R20 and R22 are in each instance independently selected from the group consisting of hydrogen, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and wherein the C1_6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are ally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C1_4 alkyl, acylamino, oxo, NO; 6021126, -CN, C1_3 alkoxy, aryloxy, -CF3, -OCF3, -OCH2CF3, -C(O)-NH2, aryl, cycloalkyl and heteroaryl; wherein said aryl is optionally fiarther substituted with C1_4 alkyl or cycloalkyl; or when R20 and R22 are ed to a common nitrogen atom R20 and R22 may join to form a heterocyclyl or heteroaryl which is then optionally substituted with one, two or three tuents independently selected from the group consisting of yl, halo, C1_4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -N02, -SOZR26, -CN, C1_3 alkoxy, -CF3, -OCF3, aryl, heteroaryl and cycloalkyl; and WO 06463 each R26 is independently selected from the group consisting of hydrogen, C1_4 alkyl, aryl and cycloalkyl; n the C1_4 alkyl, aryl and cycloalkyl may be fiarther tuted with from 1 to 3 substituents independently ed from the group consisting of hydroxyl, halo, C1_4 alkoxy, -CF3 and -OCF3; or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.
In some embodiments, R1 is aryl optionally tuted with -O-R20 or C1_6 alkyl, wherein said C1_6 alkyl is optionally tuted with one, two or three halo.
[0125] In some embodiments, R1 is aryl optionally tuted with -O-R20 or C1_6 alkyl, wherein said C1_6 alkyl is optionally substituted with one, two or three halo.
F 0 In some embodiments, R1 is xi)?“ FT <1, In some embodiments, n is 0.
In some embodiments, R5 is hydrogen or C1_6 alkyl.
[0129] In some embodiments, R5 is hydrogen or methyl.
In some embodiments, R6 is C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, C1_6 alkyl, cycloalkyl, aryl, heteroaryl, -C(O)-R20, -C(O)-OR20 and -O-R20; wherein said C1_6 alkyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, C1_6 alkyl or heteroaryl; and wherein said C1_6 alkyl is optionally fiarther substituted with one, two or three halo.
In some embodiments, R6 is selected from the group consisting of (l-methyl-lH- benzo[d]imidazolyl)methyl, (1 -methyl- 1 H-imidazolyl)methyl, (1 -0X0pyrimidin- 2-ylmethyl)pyrrolidinyl, (l-oxo-tertbutoxymethyl)pyrrolidinyl, (3-fluoropyridin yl)methyl, ifluoromethyl)pyridinyl)methyl, l-(pyrimidinylmethyl)pyrrolidin yl, lH-tetrazol-S-yl, 2-(lH-imidazol-l-yl)ethyl, 2-(2-chlorophenoxy)ethyl, 2-(pyridin ethyl, 2,2,2-trifluoroethyl, 2-phenoxyethyl, 6-(trifluoromethyl)pyridinyl, benzyl, cyclopropyl, cyclopropylmethyl, , pyridinyl, pyridinylmethyl, pyrimidin ylmethyl and pyrrolidinyl.
In some embodiments, R5 and R6 join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said cyclyl or heteroaryl is ally tuted with one, two or three substituents independently selected from the group consisting of halo, C1_6 alkyl, cycloalkyl, cyclyl, aryl, heteroaryl, oxo, -CN, -O-R20, -N(R20)(R22), )-C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; and wherein said C1_6 alkyl or heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, heteroaryl and -O-R20.
In some embodiments, R5 and R6 join together with the atom to which they are attached to form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, C1_6 alkyl, cycloalkyl, heterocyclyl, heteroaryl, oxo, -O-R20, -N(R20)(R22), )-C(O)-R20 and -N(R20)-C(O)-OR20; and wherein said C1_6 alkyl or heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo and -O-R20.
In some embodiments, R5 and R6 join together with the atom to which they are attached to form a heterocyclyl selected from the group consisting of N N , 9 (Mm(106: In some embodiments, R1 is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; wherein said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, -CN, -SF5, 3)3, , -S-R20, R20, -C(O)-OR20, -N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-C(O)-OR22, -N(R20)-S(=O)2-R26, -S(=O)2-R20, -O-S(=O)2-R20, -S(=O)2-N(R20)(R22), c1.6 alkyl, c2.4 alkenyl, c2.4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and 2012/045021 wherein said C1_6 alkyl, C2_4 alkenyl, C2_4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, phenyl, heterocyclyl, heteroaryl, C1_6 alkyl, cycloalkyl, -N(R20)(R22), -C(O)-R20, -C(O)—OR20, -C(O)- N(R20)(R22), -CN and -O-R20; n is 0; R5 is hydrogen or C1_6 alkyl; and R6 is C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, lkyl, aryl, heteroaryl or heterocyclyl are ally tuted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), R20, -C(O)-OR20, -C(O)— N(R20)(R22), -CN and -O-R20; wherein said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, lkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally fiarther substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, )(R22), -C(O)-R20, -C(O)-OR20; or R5 and R6 can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three tuents independently selected from the group consisting of halo, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, R20, -N(R20)(R22), )-C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; wherein said C1_6 alkyl or heterocyclyl is ally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, heteroaryl and -O-R20.
In some ments, R1 is aryl; wherein said aryl is optionally substituted with one, two or three tuents independently selected from the group consisting of halo, -N02, -CN, -SF5, -Si(CH3)3, -O-R20, -S-R20, -C(O)—R20, -C(O)—OR20, -N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-C(O)-OR22, -N(R20)-S(=O)2-R26, -S(=O)2-R20, -O-S(=O)2-R20, -S(=O)2-N(R20)(R22), C1_6 alkyl, C2_4 alkenyl, C2_4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1_6 alkyl, C2_4 alkenyl, C2_4 l, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents ndently selected from the group consisting of halo, -N02, , heterocyclyl, heteroaryl, C1_6 alkyl, cycloalkyl, -N(R20)(R22), -C(O)-R20, -C(O)—OR20, -C(O)- N(R20)(R22), -CN and -O-R20; n is 0; R5 is hydrogen or C1_6 alkyl; and R6 is C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, aryl or cyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)— N(R20)(R22), -CN and -O-R20; wherein said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents ndently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or aryl are optionally fiarther substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R20, OR20; or R5 and R6 can join together with the atom to which they are attached to form a heterocyclyl or aryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, R20, -N(R20)(R22), -N(R20)-C(O)-R20, )-C(O)-OR20 and -C(O)-OR20; wherein said C1_6 alkyl or heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, heteroaryl and .
In some embodiments, R1 is aryl optionally substituted with -O-R20 or C1_6 alkyl; wherein said C1_6 alkyl is optionally tuted with one, two or three halo; n is 0; R5 is hydrogen or C145 alkyl; and R6 is C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents ndently selected from the group consisting of halo, -N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)— N(R20)(R22), -CN and -O-R20; wherein said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 2012/045021 ndently selected from the group consisting of halo, -N02, C1- 6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, l, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally r substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R2°)(R22), -C(0)-R2°, -C(0)-0R2°; or R5 and R6 can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, R20, -N(R20)(R22), -N(R20)-C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; n said C1_6 alkyl or heterocyclyl is optionally substituted with one, two or three substituents independently ed from the group consisting of halo, oxo, heteroaryl and -O-R20.
[0138] In some embodiments, R1 is phenyl substituted with -O-CF3 or -CF3; n is 0; R5 is hydrogen or C145 alkyl; and R6 is C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), R20, -C(O)-OR20, -C(O)— N(R20)(R22), -CN and -O-R20; n said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally r substituted with one, two or three substituents ndently selected from the group consisting of halo, -N02, C1- 6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally fiarther substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20; or R5 and R6 can join together with the atom to which they are ed to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl, aryl, oxo, -CN, R20, -N(R20)(R22), -N(R20)-C(O)-R20, -N(R20)-C(O)-OR20 and -C(O)-OR20; wherein said C1_6 alkyl or heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group ting of halo, oxo, aryl and -O-R20.
[0139] In some embodiments, the compound is selected from the group consisting of: 11-1 5 -morpholino(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [ l ,4]oxazepine 11-2 N—benzyl(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo [f] [ l ,4]oxazepinamine -(pyrrolidin- l -yl)(4-(trifluoromethyl)phenyl)-2,3 - 11-3 obenzo [f] [ l ,4]oxazepine N—cyclopropyl(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [ l zepin-5 - 11-4 amine N—benzyl-N—methyl(4-(trifluoromethyl)phenyl)-2,3 - 11-5 dihydrobenzo [f] [ l ,4]oxazepinamine N—((3-fluoropyridinyl)methyl)(4-(trifluoromethyl)phenyl)—2,3- 11-9 dihydrobenzo [f] [ l ,4]oxazepinamine WO 06463 2012/045021 N—(pyridinylrnethyl)(4-(trifluor0rnethyl)phenyl)-2 3 - 11-10 , dihydrobenzo[f][1 zepinamine N—(cyclopropylmethyl)—7-(4-(trifluorornethyl)phenyl)—2,3 - 11-11 dihydrobenzo[f][1 ,4]oxazepinamine (S)—tert-butyl 1-(7-(4-(trifluoromethyl)phenyl)—2,3 -dihydr0benz0[f][1 ,4]oxazepin-5 - 11-13 y1)pyrr01idin-3 barnate N—(2-(1H-irnidazoly1)ethy1)(4-(trifluorornethyl)phenyl)-2,3 - 11-14 dihydrobenzo[f][1 ,4]oxazepinamine (S)—N,N—dimethyl(7-(4-(trifluorornethyl)phenyl)-2,3 - 11-15 dihydrobenzo [f] [ 1 ,4]oxazepin-5 rrolidin-3 -arnine N—(pyridin-Z-yl)(4-(trifluorornethyl)phenyl)—2,3 -dihydr0benz0[f][1 ,4]oxazepin- 11-19 -amine N—(2-(pyridin-Z-yloxy)ethyl)(4-(trifluoromethyl)phenyl)—2,3- 11-20 dihydrobenzo[f][1 ,4]oxazepinamine N—(2-phen0xyethy1)—7-(4-(trifluoromethyl)phenyl)-2,3 - 11-22 dihydrobenzo[f][1 ,4]oxazepinamine N—(2-(2-ch10rophenoxy)ethyl)(4-(trifluorornethyl)phenyl)-2,3- 11-24 dihydrobenzo[f][1 ,4]oxazepinamine 7-(4-(trifluorornethyl)phenyl)—N—((6-(trifluoromethyl)pyridin-Z-y1)rnethyl)-2 ,3 - 11-25 dihydrobenzo[f][1 ,4]oxazepinamine -(4-cyclopr0pylpiperaziny1)(4-(trifluor0rnethyl)phenyl)-2,3 - 11-31 dihydrobenzo[f][1 ,4]0xazepine 11-32 N—phenyl(4-(trifluorornethyl)phenyl)-2,3-dihydr0benzo [f] [ 1 ,4]oxazepinamine N—((1 y1— 1H-benzo[d]imidazo1y1)rnethyl)(4-(trifluorornethyl)phenyl)—2,3 - 11-33 dihydrobenzo[f][1 ,4]oxazepinamine N—(pyrimidin-Z-ylmethyl)(7-(4-(trifluoromethyl)phenyl)-2,3 - 11-37 dihydrobenzo [f] [ 1 ,4]oxazepin-5 -y1)pyrrolidin-3 -arnine (R)-tert-butyl methyl( 1 -(7-(4-(trifluorornethyl)phenyl)—2,3 - 11-38 dihydrobenzo [f] [ 1 ,4]OXazepin-S-y1)pyrr01idin-3 -y1)carbamate (R)-N-rnethy1—1 -(trifluoromethyl)phenyl)-2,3-dihydr0benzo [f] [ 1 ,4]oxazepin- 11-39 -y1)pyrrolidinamine (S)-tert-butyl methy1(1-(7-(4-(triflu0r0rnethyl)phenyl)-2,3- 11-40 dihydrobenzo [f] [ 1 ,4]oxazepin-S-yl)pyrrolidin-3 -y1)carbamate (S)—tert-butyl 3 -(trifluoromethyl)phenyl)—2,3 -dihydrobenzo [f] [ l ,4]oxazepin-5 - 11-43 ylamino)pyrrolidine- l -carboxylate (R)-N-(l-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f][l,4]oxazepin 11-47 yl)pyrrolidinyl)picolinamide (S)—N,N—diethyl- l -(7-(4-(trifluoromethyl)phenyl)-2,3 - 11-48 dihydrobenzo [f] [ l ,4]oxazepin-5 -yl)pyrrolidinamine (R)-tert-butyl l-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f] [ l ,4]oxazepin 11-50 yl)pyrrolidinylcarbamate (R)-N,N—dimethyl- l -(7-(4-(trifluoromethyl)phenyl)-2,3 - 11-51 dihydrobenzo [f] [ l ,4]oxazepin-5 -yl)pyrrolidinamine 11-54 yl(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo [f] [ l ,4]oxazepinamine -(3 -morpholinopyrrolidin- l -yl)(4-(trifluoromethyl)phenyl)-2,3- 11-55 dihydrobenzo [f] [ l ,4]oxazepine (S)— l -(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f][l,4]oxazepin 11-56 yl)pyrrolidinamine utyl l -(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [ l ,4]oxazepin-5 - 11-57 yl)pyrrolidinylcarbamate -(2-(pyridinyl)pyrrolidin- l -yl)(4-(trifluoromethyl)phenyl)-2,3 - 11-58 dihydrobenzo [f] [ l zepine -(3 -(pyridinyl)pyrrolidin- l -yl)(4-(trifluoromethyl)phenyl)—2,3- 11-60 dihydrobenzo [f] [ l ,4]oxazepine l-(naphthalen- l -yloxy)—3 -((R)-l -(7-(4-(trifluoromethyl)phenyl)-2 ,3 - 11-61 dihydrobenzo [f] [ l ,4]oxazepin-S rrolidin-3 -ylamino)propanol tert-butyl 3 -(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [ l ,4]oxazepin-5 - 11-62 o)pyrrolidine- l -carboxylate (R)-tert-butyl 3-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f] [ l ,4]oxazepin 11-63 ylamino)pyrrolidine- l -carboxylate or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof. 4. Alternative Embodiments
[0140] In alternative embodiments, the compound of Formula I is represented by Formula VII: wherein: nisO, l,20r3: each R10 is independently selected from the group consisting of halo, -N02, -CN, -SF5, -Si(CH3)3, -O-R20, -S-R20, -C(O)—R20, -C(O)—OR20, -N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-C(O)-OR22, -N(R20)-S(=O)2-R26, -S(=O)2-R20, -S(=O)2-N(R20)(R22), c1.6 alkyl, c2.4 alkenyl, c2.4 l, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1_6 alkyl, C2_4 alkenyl, C2_4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, phenyl, heterocyclyl, heteroaryl, C1_6 alkyl, lkyl, )(R22), -C(O)-R20, OR20, -C(O)—N(R20)(R22), -CN and -O-R20; R2 is hydrogen, €1-15 alkyl, -C(O)-R20, -C(O)—OR26, -C(O)—N(R26)(R28), -N(R20)-S(=O)2-R20, lkyl, aryl, heteroaryl or heterocyclyl; wherein said C145 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C1_6 alkyl, C2_4 alkynyl, halo, -N02, lkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN, oxo and -O-R20; wherein said C1_6 alkyl, lkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, cycloalkyl, aryl, cyclyl or heteroaryl are optionally fiarther substituted with one, two or three tuents independently selected from the group consisting of halo, -N02, -CF3, -N(R20)(R22), -C(O)-R20, OR20, -C(O)-N(R20)(R22), -CN, -S(O)2-R20 and —0— R20' R5 is hydrogen, C145 alkyl, C1_4 alkoxy, -C(O)-O-R26, -C(O)—N(R26)(R28), -N(R20)-S(=O)2-R20, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C145 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN and ; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and ; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally fiarther substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)—N(R20)(R22), -CN and -O-R20; or R2 and R5 can join together with the atom to which they are attached to form a heterocyclyl or aryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting ofc1_15 alkyl, cycloalkyl, heteroaryl, , -N(R20)(R22), -N(R20)-C(O)-OR20 and OR20; and wherein said C145 alkyl is optionally tuted with one, two or three tuents independently selected from the group consisting of halo and heteroaryl; R20 and R22 are in each instance independently selected from the group consisting of hydrogen, C1-15 alkyl, C215 alkenyl, C215 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and wherein the C1-15 alkyl, C215 alkenyl, C215 alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are ally substituted with one, two or three substituents ndently ed from the group consisting of hydroxyl, halo, C1_4 alkyl, acylamino, -N02, -SOZR26, -CN, C1_3 alkoxy, -CF3, -OCF3, F3, -C(O)-NH2, aryl, cycloalkyl and heteroaryl; wherein said heteroaryl is optionally fiarther substituted with C1_4 alkyl or cycloalkyl; or when R20 and R22 are attached to a common en atom R20 and R22 may join to form a heterocyclic or heteroaryl ring which is then optionally tuted with one, two or three substituents independently selected from the group consisting of yl, halo, C1_4 alkyl, l, aryl, aryloxy, aralkyloxy, acylamino, -N02, -SOzR26, -CN, C1_3 alkoxy, -CF3, -OCF3, aryl, heteroaryl and cycloalkyl; R25 is in each instance independently a covalent bond or C1-3 alkylene optionally substituted with one or two C1-3 alkyl groups; and R26 and R28 are in each instance independently selected from the group consisting of hydrogen, C1_4 alkyl, aryl and cycloalkyl; and wherein the C1_4 alkyl, aryl and cycloalkyl may be fiarther substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C1_4 alkoxy, -CF3 and -OCF3; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof.
[0141] In some embodiments, when R2 and R5 join together with the atom to which they are ed to form an optionally substituted imidazolyl, the imidazolyl it is not directly substituted with an optionally substituted triazolyl, or R1 is not ally substituted pyrazolyl, 2-pyridinonyl or 2-fluoropyridinyl.
In some embodiments, R2 and R5 are joined together with the atom to which they are attached to form a heterocyclyl or heteroaryl; 2012/045021 wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents ndently selected from the group consisting of €1-15 alkyl, cycloalkyl and heteroaryl.
In some embodiments, R2 and R5 are joined together with the atom to which they NW N, L2: LN ,LWNN \ 3/ are attached to formbh" or 3W“ In some ments, R10 is 4-trifluoromethyl.
In some embodiments, the compound is selected from the group consisting of opropyl- l 0-(4-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f] [ l ,2,4]triazolo[4,3- d] [ l ,4]oxazepine; l 0 3 -methyl- 1 0-(4-(trifluoromethyl)phenyl)-5 ,6-dihydrobenzo [f]imidazo[ l ,2- d] [ l ,4]oxazepine; and 3 -(pyrimidinyl)- l 0-(4-(trifluoromethyl)phenyl)—5 ,6-dihydrobenzo [f]imidazo[ l ,2- d] [ l ,4]oxazepine; or a pharmaceutically acceptable salt, ester, hydrate, e, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or g thereof.
. Further Embodiments In some embodiments, the nds provided by the present disclosure are effective in the treatment of ions or diseases known to respond to administration of late sodium channel blockers, including but not limited to cardiovascular diseases such as atrial and ventricular arrhythmias, including atrial fibrillation, Prinzmetal’s nt) angina, stable angina, unstable angina, ischemia and reperfusion injury in cardiac, kidney, liver and the brain, exercise induced angina, ary hypertension, tive heart disease including diastolic and systolic heart failure, and myocardial infarction. In some embodiments, compounds provided by the present disclosure which function as late sodium channel rs may be used in the treatment of diseases affecting the neuromuscular system resulting in pain, itching, seizures, or paralysis, or in the treatment of diabetes or reduced insulin sensitivity, and disease states related to diabetes, such as diabetic peripheral neuropathy.
Certain compounds of the disclosure may also possess a ent activity in modulating neuronal sodium channels, i.e., NaV 1.1., 1.2, 1.3, 1.5, 1.7, and/or 1.8, and may have appropriate pharmacokinetic properties such that they may be active with regard to the central and/or peripheral nervous system. Consequently, some compounds of the disclosure may also be of use in the treatment of epilepsy or pain or itching or heachache of a neuropathic origin.
In one ment, this disclosure provides a method of treating a disease state in a mammal that is able by treatment with an agent capable of reducing late sodium current, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula 1, IA, IE or VII or other formulas or compounds sed . In another embodiment, the disease state is a cardiovascular disease selected from one or more of atrial and cular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal’s (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, ary hypertension, and intermittent claudication.
In another embodiment, the disease state is diabetes or diabetic peripheral athy. In a further embodiment, the disease state results in one or more of neuropathic pain, epilepsy, heachache or sis. , seizures, In one ment, this disclosure provides a method of treating diabetes in a mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula 1, IA, IE or VII or other formulas or compounds disclosed herein. Diabetes mellitus is a disease characterized by hyperglycemia; altered metabolism of lipids, carbohydrates and proteins; and an increased risk of complications from vascular disease. Diabetes is an increasing public health problem, as it is associated with both increasing age and y.
There are two major types of diabetes mellitus: 1) Type I, also known as insulin ent diabetes (IDDM) and 2) Type II, also known as insulin independent or non- insulin dependent diabetes ). Both types of diabetes mellitus are due to insufficient s of circulating insulin and/or a se in the response of peripheral tissue to insulin.
Type I diabetes results from the body's failure to produce insulin, the hormone that "unlocks" the cells of the body, allowing glucose to enter and filel them. The complications of Type I diabetes include heart disease and stroke; retinopathy (eye disease); kidney disease (nephropathy); neuropathy (nerve damage); as well as maintenance of good skin, foot and oral health.
Type II diabetes results from the body's inability to either produce enough insulin or the cells inability to use the insulin that is naturally produced by the body. The condition where the body is not able to optimally use insulin is called insulin ance.
Type II diabetes is often accompanied by high blood pressure and this may contribute to heart disease. In patients with type II diabetes mellitus, stress, infection, and medications (such as corticosteroids) can also lead to severely elevated blood sugar levels.
Accompanied by dehydration, severe blood sugar elevation in patients with type II diabetes can lead to an increase in blood osmolality (hyperosmolar state). This condition can lead to coma.
[0154] It has been ted that ranolazine (RANEXA®, a ive inhibitor of INaL) may be an antidiabetic agent that causes B-cell preservation and enhances n secretion in a e-dependent manner in diabetic mice (see, Y. Ning et al. J Pharmacol Exp Ther. 2011, 337(1), 50-8). Therefore it is plated that the compounds of Formula 1, IA, 1B or VII or other formulas or compounds disclosed herein can be used as antidiabetic agents for the treatment of diabetes. 6. ceutical itions and Administration Compounds provided in accordance with the present sure are usually administered in the form of pharmaceutical compositions. This disclosure therefore provides ceutical compositions that contain, as the active ingredient, one or more of the compounds described, or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable excipients, rs, including inert solid ts and fillers, ts, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. The pharmaceutical compositions may be administered alone or in combination with other eutic agents.
Such compositions are prepared in a manner well known in the pharmaceutical art (see, e. g., Remington’s Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T.
Rhodes, Eds.) The pharmaceutical compositions may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar ies, for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.
[0157] One mode for administration is parenteral, ularly by injection. The forms in which the novel compositions of the present disclosure may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a e aqueous solution, and similar ceutical vehicles. Aqueous solutions in saline are also conventionally used for injection, but less preferred in the context of the present disclosure. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and ble oils may also be employed. The proper y can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the ed particle size in the case of sion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifilngal agents, for example, parabens, butanol, phenol, sorbic acid, thimerosal, and the like.
Sterile inj ectable ons are prepared by incorporating a compound according to the present disclosure in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization.
Generally, dispersions are prepared by incorporating the various sterilized active ients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those ated above. In the case of sterile powders for the preparation of sterile inj ectable solutions, the preferred s of ation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any onal desired ient from a previously sterile-filtered solution thereof Preferably, for parenteral administration, sterile injectable solutions are prepared ning a therapeutically effective amount, e. g., 0.1 to 700 mg, of a compound bed herein. It will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative ty, the age, , and response of the individual patient, the severity of the patient’s symptoms, and the like.
Oral administration is another route for administration of compounds in accordance with the disclosure. Administration may be via capsule or enteric coated tablets, or the like. In making the ceutical compositions that include at least one compound described herein, the active ient is y diluted by an excipient and/or enclosed within such a carrier that can be in the form of a e, sachet, paper or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi- solid, or liquid al (as above), which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, ol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, nylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, ium te, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
The compositions of the disclosure can be formulated so as to provide quick, sustained or d release of the active ient after administration to the patient by employing ures known in the art. Controlled release drug delivery systems for oral administration include c pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of lled release systems are given in US. Patent Nos. 3,845,770; 4,326,525; 4,902,514; and ,616,345. Another formulation for use in the methods of the present disclosure employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infiJsion of the compounds of the present disclosure in controlled amounts. The construction and use of transdermal patches for the ry of pharmaceutical agents is well known in the art. See, e.g., US. Patent Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of ceutical agents.
The itions are preferably formulated in a unit dosage form. The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable ceutical excipient (e.g., a tablet, capsule, ampoule). The compounds are generally administered in a pharmaceutically ive amount. Preferably, for oral administration, each dosage unit contains from 1 mg to 2 g, or alternatively, or 100 mg to 500 mg, of a compound described herein, and for parenteral administration, preferably from 0.1 mg to 700 mg, or alternatively, 0.1 mg to 100 mg, of a compound a compound described herein. It will be tood, however, that the amount of the nd actually administered usually will be determined by a physician, in the light of the relevant stances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative ty, the age, weight, and response of the individual patient, the severity of the patient’s symptoms, and the like.
For preparing solid compositions such as tablets, the principal active ient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a neous mixture of a compound of the present sure. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is sed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
The tablets or pills of the present disclosure may be coated or otherwise compounded to e a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can comprise an inner dosage and an outer dosage ent, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of als can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
Compositions for tion or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic ts, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases.
Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent ve pressure ing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate .
Combination Therapy Patients being treated by administration of the late sodium channel rs of the disclosure often exhibit diseases or conditions that benefit from treatment with other therapeutic agents. These diseases or conditions can be of cardiovascular nature or can be related to ary disorders, metabolic disorders, gastrointestinal disorders and the like. Additionally, some coronary patients being treated by administration of the late sodium channel blockers of the disclosure exhibit conditions that can benefit from treatment with therapeutic agents that are otics, analgesics, and/or pressants and anti-anxiety agents. vascular Agent Combination Therapy
[0167] Cardiovascular related diseases or conditions that can benefit from a combination treatment of the late sodium channel blockers of the disclosure with other therapeutic agents include, t limitation, angina including stable angina, unstable angina (UA), exercised-induced angina, variant angina, hmias, intermittent claudication, myocardial infarction including non-STE myocardial tion (NSTEMI), pulmonary ension including ary arterial hypertension, heart failure including congestive (or chronic) heart failure and diastolic heart failure and heart failure with preserved ejection fraction (diastolic dysfunction), acute heart failure, or recurrent ischemia.
Therapeutic agents le for treating cardiovascular related diseases or conditions include anti-anginals, heart e agents, antithrombotic agents, antiarrhythmic agents, antihypertensive agents, and lipid lowering agents.
The co-administration of the late sodium channel blockers of the disclosure with therapeutic agents suitable for treating cardiovascular related conditions allows enhancement in the standard of care therapy the patient is currently receiving. In some embodiments, the late sodium channel blockers of the disclosure are inistered with ranolazine (RANEXA®).
Anti-anginals Anti-anginals include beta-blockers, m channel blockers, and nitrates.
Beta rs reduce the heart's need for oxygen by reducing its workload resulting in a decreased heart rate and less vigorous heart contraction. Examples of beta-blockers include acebutolol (Sectral®), atenolol (Tenormin®), betaxolol (Kerlone®), bisoprolol/hydrochlorothiazide (Ziac®), bisoprolol (Zebeta®), carteolol (Cartrol®), esmolol (Brevibloc®), labetalol (Normodyne®, Trandate®), metoprolol (Lopressor®, Toprol® XL), nadolol (Corgard®), propranolol (Inderal®), l ace®), and timolol (Blocadren®).
[0171] es dilate the es and veins thereby increasing ry blood flow and decreasing blood pressure. Examples of nitrates include nitroglycerin, nitrate patches, bide dinitrate, and isosorbidemononitrate.
Calcium channel blockers prevent the normal flow of calcium into the cells of the heart and blood vessels g the blood vessels to relax thereby sing the supply of blood and oxygen to the heart. Examples of calcium channel blockers include amlodipine (Norvasc®, Lotrel®), il (Vascor®), diltiazem (Cardizem®, Tiazac®), felodipine (Plendil®), nifedipine (Adalat®, Procardia®), nimodipine (Nimotop®), nisoldipine (Sular®), verapamil (Calan®, Isoptin®, Verelan®), and nicardipine.
Heart Failure Agents Agents used to treat heart failure include diuretics, ACE inhibitors, vasodilators, and cardiac glycosides. Diuretics ate excess fluids in the tissues and circulation thereby relieving many of the symptoms of heart failure. es of diuretics include hydrochlorothiazide, metolazone (Zaroxolyn®), furosemide (Lasix®), nide (Bumex®), spironolactone (Aldactone®), and eplerenone (Inspra®).
Angiotensin converting enzyme (ACE) inhibitors reduce the workload on the heart by expanding the blood vessels and decreasing resistance to blood flow. Examples ofACE tors include benazepril (Lotensin®), captopril (Capoten®), enalapril (Vasotec®), fosinopril (Monopril®), lisinopril (Prinivil®, Zestril®), moexipril (Univasc®), perindopril (Aceon®), quinapril (Accupril®), ramipril (Altace®), and trandolapril Vasodilators reduce pressure on the blood vessels by making them relax and expand. Examples of vasodilators include hydralazine, diazoxide, prazosin, clonidine, and methyldopa. ACE inhibitors, nitrates, ium channel tors, and calcium channel blockers also act as vasodilators.
Cardiac glycosides are compounds that increase the force of the heart’s contractions. These nds strengthen the g capacity of the heart and improve irregular heartbeat activity. es of c ides include digitalis, digoxin, and digitoxin.
Antithrombotic Agents Antithrombotics inhibit the clotting ability of the blood. There are three main types of antithrombotics - platelet inhibitors, anticoagulants, and thrombolytic agents.
Platelet inhibitors inhibit the clotting activity of platelets, thereby reducing clotting in the arteries. es of platelet inhibitors include acetylsalicylic acid (aspirin), ticlopidine, clopidogrel (Plavix®), prasugrel (Effient®), dipyridamole, cilostazol, tine sulf1npyrazone, dipyridamole, thacin, and glycoprotein llb/llla inhibitors, such as abciximab, tirof1ban, and eptifibatide (Integrelin®). Beta blockers and calcium channel rs also have a platelet-inhibiting effect.
[0178] Anticoagulants prevent blood clots from growing larger and prevent the formation of new clots. Examples of anticoagulants include bivalirudin (Angiomax®), warfarin (Coumadin®), unfractionated heparin, low molecular weight heparin, danaparoid, lepirudin, and argatroban.
Thrombolytic agents act to break down an ng blood clot. Examples of thrombolytic agents include streptokinase, urokinase, and tenecteplase (TNK), and tissue plasminogen activator (t-PA).
Antiarrhythml'c agents Antiarrhythmic agents are used to treat ers of the heart rate and rhythm.
Examples of antiarrhythmic agents include amiodarone, dronedarone, quinidine, procainamide, lidocaine, and propafenone. Cardiac glycosides and beta blockers are also used as antiarrhythmic agents.
Combinations with amiodarone and dronedarone are of particular interest (see US. Patent Application Publication No. 2010/0056536 and US. Patent Application Publication No. 201 1/0183990, the ty of which are incorporated herein).
Antihypertensz've agents
[0182] Antihypertensive agents are used to treat hypertension, a condition in which the blood re is tently higher than normal. Hypertension is associated with many aspects of cardiovascular disease, including congestive heart failure, atherosclerosis, and clot formation. Examples of antihypertensive agents include alpha-l-adrenergic antagonists, such as in (Minipress®), doxazosin te ra®), prazosin hydrochloride (Minipress®), prazosin, polythiazide (Minizide®), and terazosin hydrochloride (Hytrin®); beta-adrenergic antagonists, such as propranolol (Inderal®), nadolol (Corgard®), timolol dren®), metoprolol (Lopressor®), and ol (Visken®); central alpha-adrenoceptor agonists, such as clonidine hydrochloride (Catapres®), clonidine hydrochloride and chlorthalidone (Clorpres®, Combipres®), guanabenz Acetate (Wytensin®), guanfacine hydrochloride ®), methyldopa (Aldomet®), methyldopa and chlorothiazide (Aldoclor®), methyldopa and hydrochlorothiazide (Aldoril®); combined alpha/beta-adrenergic antagonists, such as labetalol (Normodyne®, Trandate®), carvedilol (Coreg®); adrenergic neuron blocking agents, such as guanethidine (Ismelin®), reserpine (Serpasil®); central nervous system- acting pertensives, such as clonidine (Catapres®), methyldopa (Aldomet®), guanabenz (Wytensin®); anti-angiotensin 11 agents; ACE inhibitors, such as perindopril WO 06463 (Aceon®) captopril (Capoten®), enalapril (Vasotec®), pril vil®, Zestril®); angiotensin-II receptor antagonists, such as candesartan (Atacand®), rtan (Teveten®), irbesartan (Avapro®), losartan (Cozaar®), telmisartan (Micardis®), valsartan (Diovan®); calcium channel rs, such as verapamil ®, Isoptin®), diltiazem (Cardizem®), nifedipine t®, Procardia®); diuretics; direct vasodilators, such as nitroprusside de®), diazoxide stat® IV), azine (Apresoline®), minoxidil (Loniten®), verapamil; and potassium channel activators, such as aprikalim, bimakalim, cromakalim, emakalim, nicorandil, and pinacidil.
Lipid Lowering Agents
[0183] Lipid lowering agents are used to lower the amounts of cholesterol or fatty sugars present in the blood. Examples of lipid lowering agents include bezafibrate (Bezalip®), ciprofibrate (Modalim®), and statins, such as atorvastatin (Lipitor®), fluvastatin (Lescol®), atin or®, Altocor®), mevastatin, pitavastatin (Livalo®, Pitava®) pravastatin (Lipostat®), rosuvastatin (Crestor®), and simvastatin (Zocor®).
[0184] In this disclosure, the patient presenting with an acute ry disease event often suffers from secondary medical conditions such as one or more of a metabolic disorder, a pulmonary disorder, a peripheral vascular disorder, or a gastrointestinal disorder. Such patients can benefit from treatment of a ation therapy comprising administering to the patient a compound as disclosed herein (e.g., Formula 1, IA, 1B or VII) in combination with at least one therapeutic agent.
Pulmonary Disorders Combination Therapy Pulmonary disorder refers to any disease or condition related to the lungs.
Examples of pulmonary disorders include, without limitation, asthma, chronic ctive pulmonary disease (COPD), bronchitis, and emphysema.
[0186] Examples of therapeutics agents used to treat pulmonary disorders include bronchodilators including beta2 ts and olinergics, corticosteroids, and electrolyte supplements. Specific examples of therapeutic agents used to treat pulmonary disorders include epinephrine, terbutaline (Brethaire®, Bricanyl®), albuterol (Proventil®), salmeterol (Serevent®, Serevent Diskus®), theophylline, ipratropium bromide (Atrovent®), tiotropium (Spiriva®), methylprednisolone (Solu-Medrol®, Medrol®), magnesium, and potassium.
Metabolic Disorders Combination Therapy Examples of metabolic ers include, without limitation, es, including type I and type II diabetes, metabolic syndrome, dyslipidemia, y, glucose intolerance, hypertension, elevated serum cholesterol, and elevated triglycerides.
Examples of therapeutic agents used to treat metabolic disorders include antihypertensive agents and lipid lowering agents, as described in the section “Cardiovascular Agent Combination Therapy” above. Additional therapeutic agents used to treat metabolic disorders include insulin, sulfonylureas, biguanides, alpha-glucosidase inhibitors, and incretin mimetics.
Peripheral Vascular Disorders ation Therapy eral vascular disorders are disorders related to the blood vessels (arteries and veins) d outside the heart and brain, including, for example eral arterial disease (PAD), a condition that develops when the arteries that supply blood to the internal organs, arms, and legs become completely or partially d as a result of atherosclerosis.
Gastrointestinal Disorders Combination Therapy Gastrointestinal disorders refer to diseases and conditions associated with the gastrointestinal tract. Examples of gastrointestinal disorders include gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), gastroenteritis, gastritis and peptic ulcer e, and pancreatitis.
Examples of therapeutic agents used to treat gastrointestinal disorders include proton pump tors, such as pantoprazole (Protonix®), lansoprazole (Prevacid®), razole (Nexium®), omeprazole (Prilosec®), rabeprazole; H2 blockers, such as cimetidine (Tagamet®), ranitidine (Zantac®), dine (Pepcid®), nizatidine (Axid®); prostaglandins, such as misoprostol (Cytotec®); sucralfate; and antacids.
Antibiotics, analgesics, antidepressants and anti-anxiety agents Combination y Patients presenting with an acute coronary disease event may exhibit conditions that benefit from stration of therapeutic agent or agents that are antibiotics, analgesics, antidepressant and anti-anxiety agents in combination with a compound as disclosed herein (e. g., Formula 1, IA, 1B or VII).
WO 06463 Antibiotics Antibiotics are therapeutic agents that kill, or stop the growth of, microorganisms, including both bacteria and fungi. Example of antibiotic agents include am antibiotics, including penicillins (amoxicillin), cephalosporins, such as cefazolin, cefilroxime, cefadroxil (Duricef®), cephalexin (Keflex®), cephradine (Velosef®), cefaclor r®), cefuroxime axtel (Ceftin®), cefprozil (Cefzil®), loracarbef (Lorabid®), e (Suprax®), cefpodoxime il (Vantin®), ceftibuten (Cedax®), cefdinir (Omnicef®), ceftriaxone (Rocephin®), carbapenems, and ctams; tetracyclines, such as tetracycline; macrolide antibiotics, such as erythromycin; aminoglycosides, such as gentamicin, tobramycin, amikacin; ones such as oxacin; cyclic peptides, such as ycin, streptogramins, polymyxins; lincosamides, such as clindamycin; oxazolidinoes, such as linezolid; and sulfa antibiotics, such as sulfisoxazole.
Analgesics
[0194] Analgesics are eutic agents that are used to relieve pain. Examples of analgesics include opiates and morphinomimetics, such as fentanyl and morphine; paracetamol; NSAIDs, and COX-2 inhibitors. Given the abilty of the late sodium channel blockers of the disclosure to treat neuropathic pain Via inhibition of the Na; 1.7 and 1.8 sodium channels, combination with analgesics are ularly invisioned. See US.
Patent Application Publication 20090203707.
Antidepressant and Anti-anxiety agents Antidepressant and anti-anxiety agents include those agents used to treat anxiety ers, depression, and those used as sedatives and illers. Examples of antidepressant and anti-anxiety agents include benzodiazepines, such as diazepam, lorazepam, and midazolam; enzodiazepines; barbiturates; glutethimide; chloral hydrate; meprobamate; line (Zoloft®, Lustral®, Apo-Sertral®, Asentra®, Gladem®, Serlift®, Stimuloton®); escitalopram (Lexapro®, Cipralex®); fluoxetine (Prozac®, Sarafem®, Fluctin®, Fontex®, Prodep®, Fludep®, Lovan®); venlafaxine (Effexor® XR, Efexor®); citalopram (Celexa®, Cipramil®, Talohexane®); paroxetine (Paxil®, Seroxat®, Aropax®); trazodone (Desyrel®); amitriptyline (ElaVil®); and bupropion (Wellbutrin®, Zyban®).
Accordingly, one aspect of the disclosure provides for a ition comprising the late sodium channel blockers of the disclosure and at least one therapeutic agent. In an ative embodiment, the composition comprises the late sodium channel blockers of the disclosure and at least two therapeutic agents. In further alternative embodiments, the ition comprises the late sodium channel blockers of the disclosure and at least three therapeutic agents, the late sodium channel blockers of the disclosure and at least four therapeutic agents, or the late sodium channel blockers of the disclosure and at least five therapeutic .
The methods of combination therapy include co-administration of a single formulation ning the the late sodium channel blockers of the disclosure and therapeutic agent or agents, essentially contemporaneous administration of more than one formulation comprising the late sodium channel blocker of the sure and therapeutic agent or agents, and consecutive administration of a late sodium channel blocker of the disclosure and therapeutic agent or agents, in any order, n preferably there is a time period where the late sodium channel blocker of the disclosure and therapeutic agent or agents simultaneously exert their therapeutic affect. 7. Synthesis ofExample nds The compounds of the sure may be prepared using methods disclosed herein and routine modifications thereof which will be apparent given the disclosure herein and methods well known in the art. Conventional and nown synthetic s may be used in addition to the teachings . The synthesis of typical compounds described herein, e.g. compounds having structures described by one or more of Formula 1, IA, 1B or VII or other as or compounds disclosed herein, may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g. from Sigma Aldrich or other chemical ers.
General Syntheses Typical embodiments of compounds in accordance with the present disclosure may be synthesized using the general reaction schemes described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to e corresponding products. Given a desired t for which the substituent groups are defined, the necessary starting materials generally may be determined by inspection.
Starting als are typically obtained from commercial sources or synthesized using published s. For synthesizing compounds which are ments of the present disclosure, inspection of the structure of the nd to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein.
Synthetic Reaction Parameters The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
Additionally, as will be apparent to those d in the art, conventional protecting groups may be ary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various fianctional groups as well as suitable conditions for protecting and deprotecting particular fianctional groups are well known in the art. For example, numerous protecting groups are described in T. W.
Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and references cited therein.
[0202] Furthermore, the compounds of this disclosure may contain one or more chiral centers. ingly, if desired, such compounds can be prepared or isolated as pure isomers, i.e., as dual enantiomers or diastereomers or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be ed using, for example, optically active ng materials or selective reagents well-known in the art. Alternatively, racemic es of such compounds can be separated using, for example, chiral column chromatography, chiral ing agents, and the like.
The starting materials for the following ons are lly known compounds or can be prepared by known procedures or obvious modifications thereof.
For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, rnia, USA), Emka-Chemce or Sigma (St. Louis, Missouri, USA). Others may be prepared by procedures or obvious modifications f, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplementals (Elsevier Science Publishers, 1989) c Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley, and Sons, 5th Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
The terms “solvent,” “inert organic solvent” or “inert solvent” refer to a solvent inert under the conditions of the reaction being described in ction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, ol, ne and the like). Unless specified to the contrary, the solvents used in the reactions of the present disclosure are inert organic solvents, and the reactions are d out under an inert gas, preferably nitrogen.
The term “q.s.” means adding a quantity sufficient to achieve a stated filnction, e.g., to bring a on to the desired volume (i.e., 100%).
Synthesis oft/w Compounds ofFormula I The compounds of Formula I are typically prepared by first providing the molecular core 1-1 and then attaching the desired -R1 tuent using suitable coupling conditions (e.g., Suzuki coupling). This process is show below in Scheme 1 for the synthesis of a compound of Formula I. 2012/045021 Scheme 1 Y\ Pd—cat, base, solvent heat or microwave irradiation Br (ii—| Z> \ R1—I / Y\Z) 4\(R3>n ' O R1 R1 ,0 / \ or B<OH>2 E? OJ\(R3)n 1-1 0 1-2 In general, a halogenated compound of formula 1-1, in this case a brominated nd, is d with an appropriately substituted boronic acid derivative of formula H)2 or a boronic ester thereof, in an inert solvent, for example s N,N— dimethylformamide, in the presence of a mild base, for example potassium carbonate or sodium bicarbonate. The reaction is typically conducted in the presence of a metal catalyst with an riate ligand, for example dichlorobis(triphenylphosphine) palladium(II), at a temperature of about OOC, for about 10 minutes to about 1 hour or at a lower temperature, ie., 90-1 10°C for 2 to 5 days. When the reaction is substantially complete, the product of Formula I is isolated by conventional means.
Optional Core Synthesis In certain embodiments, the core may be synthesized before or after addition of the -R1 subsitutent (Scheme 2). For example, such an alternative route for the synthesis of compounds of formula 2-3 and 2—4 (i.e., Formulas IA and IB, respectively) is shown in Scheme 2, below.
Scheme2 ’R4 R4 CI N\ N R2 2 \ \ \ LG-R 1 I H2N_R4 I R— \N> R1 N? \ \(R3)n / \ 3 R1_' N; / OJ J (R)n OVPPTS / OJ\(R3)n 2-1 2-2 2-3 RELN’R6 RELN’R6 R1—:\ l / OJ\(R3)n In one embodiment, compounds of Formula 2-2 can be provided from the amination of compounds of Formula 2-1 with a amine of a NH2—R4.
The R2 moiety may be d to compounds of Formula 2-2 under tution reaction conditions with an appropriate t of formula LG—R2 (where LG is a leaving group such as a halo, hydroxyl, alkoxy, or the like) to afford compounds of Formula 2-3.
Typical substitution on conditions e the presence of a base, such as ssium carbonate, sodium bicarbonate, triethylamine, and the like, in a polar aprotic solvent, such as N,N-dimethylformamide, and optionally an elevated temperature of about lOO-lSOOC or in a microwave.
[0211] In one embodiment, compounds of a 2-4 can be provided from the amination of compounds of Formula 2-1 with a amine of formula NH(R5R6).
It will also be appreciated that the addition of any substituent may result in the production of a number of isomeric products any or all of which may be isolated and ed using conventional techniques.
[0213] The following examples are included to demonstrate red embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques ered by the inventor to function well in the practice of the disclosure, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many s can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.
List ofAbbreviations and Acronyms Abbreviation Meaning oC Degree Celcius anal Analytical ATP Adenosine-5'-triphosphate ATX II Anemonia sulcata toxin ACN Acetonitrile CHO Chinese hamster ovary d Doublet dd Doublet of doublets DIPEA N,N-diisopropylethylamine DMF Dimethylformamide DMSO Dimethylsulfoxide ECF Extracellular fluid EDTA Ethylenediaminetetraacetic acid EGTA Ethylene glycol tetraacetic acid g Grams HEPES (4-(2-Hydroxyethyl)— l azineethanesulfonic acid ) hERG human Ether-a-go-go Related Gene HPLC erformance liquid chromatography h Hours Hz Hertz ICso The half maximal inhibitory concentration IMR-32 Human neuroblastoma cell line J Coupling constant Kg Kilogram kHz Kilohertz M Vlolar m Vlultiplet rn/z mass-to-charge ratio M--H min/m ml/mL mmol nmol mOsmol 1’IlS Vlillisecond NMR \Iuclear magnetic nce Picoamps PPTS Pyridinium p-toluenesulfonate q.s. Quantity sufficient to achieve a stated function Rf Retention factor Second Singlet SEM Standard error of the mean TB Tonic Block TEA Triethylamine TFA Trifluoroacetic acid THF Tetrahydrofuran TTX Tetrodotoxin UDB Use Dependent Block WT Wild type al shift Hg Microgram uL/ ul Microliter uM Micromolar urn eter EXAMPLES Example 1 -(4-(trifluoromethyl)phenyl)-5,6-dihydrobenzo [f] imidazo[1,2-d] [1,4] oxazepine (Compound I-1) F0 b F 0 ° F 0 °' PC|5 NH N ) Toluene ) O O A solution of 7-(4-(triflu0r0methyl)phenyl)—3,4-dihydr0benz0[f][1,4]0xazepin- (2H)—one (3.6 g, 11.7 mmol) and phosphorous hloride (2.56g, 12.3 mmol) in e (80 rnL) was refluxed for 2 hours. The reaction mixture was trated to yield -chloro(4-(trifluoromethyl)phenyl)—2,3-dihydr0benzo[f][1,4]oxazepine and used in subsequent steps without fithher ation.
\ N\ \ NH N J PPTS O A solution of 5-chloro(4-(triflu0r0methyl)phenyl)-2,3- dihydrobenzo[f][1,4]oxazepine (11.7 mmol) in 2,2-dimeth0xyethanamine (20 rnL) was heated at 100 CC for 1 hour. The reaction mixture was concentrated to give (Z)—2,2- dimethoxy—N—(7-(4-(triflu0r0methyl)phenyl)—3 ,4-dihydr0benz0 [f] [ 1 ,4]0xazepin-5(2H)- ylidene)ethanamine as an oil. The crude material was dissolved in toluene (80 rnL) and PPTS (6.0 g) was added and the mixture was refluxed for 5 h. The reaction mixture partitioned between ethyl acetate and brine and filtered through celite. The organic layer was dried with sodium e and concentrated before being purified by silica gel chromatography (Rf = 0.15 in 2:1 hexanes/ethyl acetate) to give 10-(4- (trifluoromethyl)phenyl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine as a white solid (2.3g, 60% over three . C18H13F3N20 x TFA. 331.1 (M+1). 1H NMR (DMSO) 8 8.53 (d, J = 2.0 Hz, 1H), 7.99 (d, J = 8.0 Hz, 2H), 7.91 (dd, J = 8.0, 2.0 Hz, 1H), 7.87 (d, J = 8.0 Hz, 2H), 7.77 (d, J = 12.0 Hz, 2H), 7.30 (d, J = 8.8 Hz, 1H), 4.65 (m, 4H). ”P NMR (DMSO) 8 -59.21 (s, 3F).
Example 2 -(4-(trifluorometh0xy)phenyl)—5,6-dihydr0benzo [f] imidaz0[1,2-d] [1,4] oxazepine (Compound I-2) F O >r N \ F O (I? 0 OJ Compound I-2 was prepared according to the Examples disclosed herein using the appropriate ng materials. C18H13F3N202 X TFA. 347.1 (M+1). 1H NMR (DMSO) 8 8.45 (d, 2.0 Hz, 1H), 7.86 (m, 3H), 7.76 (d, J = 12.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.0 Hz, 1H), 4.65 (m, 4H). ”P NMR (DMSO) 8 —57.30 (s, 3F).
Example 3 -(4-(trifluoromethyl)phenyl)-5,6-dihydr0benzo[f] [1,2,4]triazolo[4,3- d] [1,4]oxazepine (Compound I-3) P235 Br NH ) acetonitrile O A solution of 7-bromo-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one (2g, 8.3 mmol) P2S5 (4.4 g, 10.0 mmol) acetonitrile (40 mL) and triethylamine (20 mL) was d for 4h. The mixture was concentrated and dissolved in dichloromethane before WO 06463 being washed three times with water. The organic layer was dried with sodium e and concentrated before being purified by silica gel chromatography (Rf = 0.35 in 2:1 hexanes/ethyl acetate) to give 7-bromo-3,4-dihydrobenzo[f][1,4]oxazepine-5(2H)—thione as yellow powder (1.3g, 61%).
S N\’NH2 N\’ N\> Br NH hydrazine formic acid Br N ) THF J O O A on of 7-bromo-3,4-dihydrobenzo[f][1,4]oxazepine-5(2H)—thione (500 mg, 1.94 mmol), anhydrous hydrazine (0.3 mL) and THF was refluxed for 1h. The reaction was concentrated and the crude hydrazonamide was taken on without r purification. A solution of 7-bromohydrazono-2,3,4,5- tetrahydrobenzo[f][1,4]oxazepine in formic acid was reluxed for 1h. The mixture was concentrated and subjected to typical Suzuki reaction conditions followed by preperative HPLC to give Compound 1-3. C17H12F3N30. 332.1 (M+l).
Example 4 3-cyclopr0pyl(4-(trifluor0methyl)phenyl)—5,6-dihydr0benz0[f] [1,2,4]triazolo[4,3- d] [1,4]oxazepine (Compound I-5) . 0 >4 Compound I-5 was prepared according to the Examples disclosed herein using the riate starting materials. C20H16F3N30 . 372.1 (M+l).
Example 5 3-methyl(4-(trifluor0methyl)phenyl)-5,6-dihydrobenzo[flimidazo[1,2- d] [1,4]oxazepine (Compound L6) Compound 1-6 was prepared according to the Examples disclosed herein using the riate starting materials. C19H15F3N20 . 345.1 (M+l).
Example 6 3-(pyrimidinyl)—10-(4-(trifluoromethyl)phenyl)—5,6-dihydrobenzo[f]imidazo[1,2- d] [1,4]oxazepine (Compound 1-7) F W3 Compound 1-7 was prepared according to the Examples disclosed herein using the appropriate starting materials. C22H15F3N4O . 409.1 (M+l).
Example 7 3-benzyl—10-(4-(trifluoromethyl)phenyl)—5,6-dihydrobenzo[f]imidazo[1,2- d] [1,4]oxazepine (Compound 1-11) Compound I-11 was prepared ing to the Examples disclosed herein using the appropriate starting materials. C25H19F3N20 . 421.1 (M+l).
Example 8 2-chloromethyl(4-(trifluoromethyl)phenyl)—5,6-dihydrobenzo [f]imidazo [1,2- d] [1,4]oxazepine (Compound 1-14) F CI Compound I-14 was ed according to the Examples disclosed herein using the appropriate ng materials. C19H14ClF3N20 . 379.4 (M+l).
Example 9 1-(10-(4-(trifluoromethyl)phenyl)—5,6-dihydrobenzo [f] imidazo[1,2-d] [1,4] oxazepin yl)ethanone (Compound 1-15)
[0224] Compound 1-15 was prepared according to the Examples disclosed herein using the appropriate starting materials. C20H15F3N20. 373.1 (M+l).
Example 10 3-methyl(4-(trifluoromethoxy)phenyl)—5,6-dihydrobenzo[f]imidazo[1,2- d] [1,4]oxazepine (Compound I-17) E100 N33, O nd I-17 was prepared according to the Examples disclosed herein using the appropriate ng materials. C19H15F3N202. 361.1 (M+l).
Example 11 opropyl—10-(4-(trifluoromethoxy)phenyl)—5,6-dihydrobenzo[f]imidazo[1,2- d] [1,4]oxazepine (Compound 1-18) Era w Compound II-5 was prepared according to the Examples disclosed herein using the riate starting materials. C21H17F3N202. 387.1 (M+l).
Example 12 yl(4-(trifluoromethyl)phenyl)—5,6-dihydrobenzo[f]imidazo[1,2- d] [1,4]oxazepine (Compound 1-19)
[0227] Compound 1-19 was prepared ing to the Examples disclosed herein using the appropriate starting materials. C19H15F3N20 . 345.1 (M+l).
Example 13 2-cyclopropyl—10-(4-(trifluoromethyl)phenyl)—5,6-dihydrobenzo[f]imidazo[1,2- d] [1,4]oxazepine (Compound 1-20) Compound II-5 was ed according to the Examples disclosed herein using the appropriate starting materials. C21H17F3N20. 371.1 (M+l).
Example 14 -morpholino(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepine (Compound II-1) F (3 F O N O\N O) Compound II-1 was prepared according to the Examples disclosed herein using the appropriate starting als. C20H19F3N202. 377.1 (M+l).
Example 15 N-benzyl—7—(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f] [1,4]oxazepinamine (Compound 11-2)
[0230] Compound II-2 was prepared according to the Examples disclosed herein using the appropriate starting materials. C23H19F3N20. 397.1 (M+l).
Example 16 -(pyrrolidinyl)—7—(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepine (Compound 11-3) Compound II-3 was prepared according to the es sed herein using the riate starting materials. C20H19F3N20. 361.1 (M+l).
Example 17 N-cyclopropyl(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f] [1,4]oxazepin amine (Compound II-4) F p F O HN O\” OJ Compound II-4 was prepared ing to the Examples disclosed herein using the appropriate starting materials. C19H17F3N20. 347.1 (M+l).
Example 18 yl—N-methyl(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepin- -amine (Compound 11-5)
[0233] Compound II-5 was prepared according to the Examples disclosed herein using the appropriate starting materials. C24H21F3N20. 411.1 (M+l). e 19 (S)—N,N-dimethyl(7-(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinyl)pyrrolidinamine (Compound 11-15) F 0 CI DIPEA, DMF, mw 100°C, 20min \N 'l'l'l'l To a anhydrous DMF solution (3 mL) of the compound A (65 mg, 0.20 mmol) and (S)—N,N-dimethylpyrrolidinamine (69 mg, 0.60 mmol) was added Hunig’s base (0.30 mL, 1.68 mmol) with stir. The reaction mixture was subjected to e microwave heating at 120°C for 20 min. The resulting mixture was d, concentrated in vaccuo, and subjected to Gilson preparative HPLC, eluting with a gradient ofACN in H20 (5% to 95%) to afford Compound 11-15 (45 mg, 0.11 mmol, 55%). LCMS m/z 404.2 (M+H), anal HPLC 100% in purity. 1H NMR (400 MHz; DMSO-d6) 5 8.72 (s, 2H); 7.93 (m, 4H ); 7.82 (d, J: 8.1 Hz, 2H); 7.31 (d, J: 8.2 Hz, 1H); 4.35 (m, 2H); PCT/U82012/045021 3.61 — 3.33 (m, 5H ); 3.16 (s, 1H); 2.77 (m, 1H); 2.15 (s, 6H); 2.07 (m, 1H); 1.79 (m, 1H).
”P NMR (400 MHz; 6) 5 -61.42 (s, 3F).
Example 20 N-(pyrimidinylmethyl)—7—(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound II-7) F HM)N\ F 0 Compound II-7 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 21 N-cyclopropyl—N-methyl(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine und 11-8) Compound II-8 was prepared according to Example 19 disclosed herein using the appropriate starting als. e 22 N-((3-fluoropyridinyl)methyl)—7—(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound II-9) F \ . 0 .1 1 / O\N OJ Compound II-9 was prepared according to Example 19 disclosed herein using the appropriate starting materials. MS m/z 416.1, M+H.
Example 23 tert-butyl 1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f] [1,4] oxazepin-S- yl)azetidinylcarbamate (Compound 11-12)
[0238] Compound 11-12 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 24 (R)—tert-butyl 1-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f] [1,4] oxazepin-S- rolidinylcarbamate und 11-50) F. 3M» F O N\N O O) Compound 11-50 was prepared according to Example 19 disclosed herein using the appropriate starting materials. MS m/z 476.1, M+H).
Example 25 (S)—tert-butyl 4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepin-S- yl)pyrrolidinylcarbamate (Compound 11-13) HN’q/e-‘ 0 FF 0 F O N 0“OJ Compound II-7 was prepared ing to Example 19 disclosed herein using the appropriate starting als. MS m/z 476.1, M+H).
Example 26 N-(2-(1H-imidazolyl)ethyl)—7—(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound 11-14) F Nrj F O HN O ‘” DJ Compound 11-14 was prepared according to Example 19 disclosed herein using the appropriate starting materials. MS m/z 401.1, M+H.
Example 27 (S)—(1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] in-S- yl)pyrrolidinyl)methanol (Compound II-16) FF 0 F0 N O“O) Compound 11-16 was ed according to Example 19 disclosed herein using the appropriate starting materials.
Example 28 N-((1-methyl—1H-imidazolyl)methyl)—7—(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound 11-17) F 1 F O '4ij O\N OJ Compound 11-17 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 29 1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepin-S-yl)azetidin amine (Compound II-18) Compound 11-18 was prepared ing to Example 19 disclosed herein using the appropriate ng materials.
Example 30 5-(4,4-difluoropiperidinyl)—7—(4—(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepine (Compound 11-21) Compound 11-21 was prepared according to e 19 disclosed herein using the appropriate starting materials.
Example 3 1 1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepinyl)pyrrolidin 01 (Compound 11-23) Compound 11-23 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 32 N-(2-(2-chlorophenoxy)ethyl)—7—(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound 11-24) nd 11-24 was prepared ing to e 19 disclosed herein using the appropriate starting materials. MS m/z 461.1, M+H.
Example 33 7-(4-(trifluoromethyl)phenyl)-N-((6-(trifluoromethyl)pyridinyl)methyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound 11-25) Compound 11-25 was ed according to Example 19 disclosed herein using the appropriate starting materials MS m/z 466.1, M+H.
Example 34 N-(lH-tetrazol-S-yl)—7-(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound 11-26) 2012/045021 Compound 11-26 was prepared according to Example 19 disclosed herein using the appropriate starting materials. MS m/z 375.1, M+H.
Example 35 7-(4-(trifluoromethyl)phenyl)—N-(6-(trifluoromethyl)pyridinyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound 11-27) F g;\N F F O HN F O\” OJ nd 11-27 was ed according to Example 19 disclosed herein using the appropriate starting materials.
Example 36 5-(4-(2,2,2-trifluoroethyl)piperazinyl)(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepine (Compound II-28) FF LN33F]: 00;} Compound 11-28 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 37 N-dimethyl—1-(7-(4-(trifluoromethyl)phenyl)—2,3- obenzo[f] [1,4]oxazepinyl)pyrrolidinamine (Compound 11-51)
[0252] Compound 11-51 was prepared according to Example 19 disclosed herein using the appropriate starting materials. MS m/z 404.1, M+H.
Example 38 N-(2,2,2-trifluoroethyl)—7—(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound 11-29) F F HN/q:F F O \N OJ Compound 11-29 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 39 4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepinyl)pyrrolidin one (Compound 11-30) Compound 11-30 was prepared according to Example 19 sed herein using the appropriate starting materials.
Example 40 -(4-methylpiperazinyl)—7-(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepine (Compound 11-52)
[0255] Compound 11-52 was prepared according to Example 19 sed herein using the appropriate starting materials.
Example 41 rt—butyl 3-methyl(7-(4-(trifluoromethyl)phenyl)—2,3- obenzo[f] [1,4] oxazepinyl)piperazine-l-carboxylate (Compound 11-53) F XENSKOK O O)\N Compound II-7 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 42 -(4-cyclopropylpiperazinyl)—7—(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepine (Compound 11-31) Compound 11-31 was ed according to Example 19 disclosed herein using the appropriate ng materials. MS m/z 416.1, M+H.
Example 43 N-phenyl—7—(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepinamine (Compound 11-54) Compound 11-54 was prepared according to e 19 disclosed herein using the appropriate starting materials. MS m/z 383.1, M+H.
Example 44 orpholinopyrrolidinyl)—7-(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepine (Compound 11-55) Compound 11-55 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 45 (S)(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepin yl)pyrrolidinamine (Compound II-56) Compound 11-56 was prepared according to Example 19 disclosed herein using the appropriate starting als. e 46 tert-butyl 1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f] [1,4] oxazepin-S- yl)pyrrolidinylcarbamate (Compound 11-57) F. (“50% Compound II-7 was prepared ing to Example 19 disclosed herein using the appropriate starting materials. MS m/z 476.1, M+H. e 47 5-(2-(pyridinyl)pyrrolidinyl)—7—(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepine (Compound 11-58) Compound 11-58 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 48 N-(pyrrolidinyl)(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f] [1,4]oxazepin- -amine (Compound 11-59) F )3NH F F O HN O \N 0) Compound 11-59 was ed according to e 19 disclosed herein using the appropriate starting materials.
Example 49 N-(1-(pyrimidinylmethyl)pyrrolidinyl)(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound 11-34) F fiN/wéN F o .N J O \N OJ Compound 11-34 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 50 dinyl(3-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepin-S- ylamino)pyrrolidinyl)methanone (Compound 11-35) F fiN/g; F O HN\N O O) Compound 11-35 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 51 pyridinyl)pyrrolidinyl)—7—(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepine (Compound 11-60)
[0266] Compound II-7 was prepared according to Example 19 disclosed herein using the riate starting materials. MS m/z 438.1, M+H.
Example 52 -(1,3'-bipyrrolidin-1'-yl)(4-(trifluoromethyl)phenyl)—2,3- obenzo[f] [1,4]oxazepine (Compound 11-36) Compound 11-36 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 53 N-(pyrimidin-Z-ylmethyl)—1-(7-(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinyl)pyrrolidinamine (Compound II-37) HNVN/ Compound 11-37 was prepared according to Example 19 disclosed herein using the appropriate starting materials. MS m/z 468.1, M+H.
Example 54 (R)—tert-butyl methyl(1-(7-(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4] oxazepinyl)pyrrolidinyl)carbamate (Compound 11-38) .F (gilt Compound 11-38 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 55 (R)—N-methyl—1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepin-S- yl)pyrrolidinamine (Compound 11-39) Compound 11-39 was prepared ing to Example 19 sed herein using the appropriate ng materials. MS m/z 390.1, M+H.
Example 56 (S)—tert-butyl (1-(7-(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepin-S-yl)pyrrolidinyl)carbamate (Compound 11-40)
[0271] Compound 11-40 was ed according to Example 19 disclosed herein using the appropriate starting materials. MS m/z 490.1, M+H.
Example 57 (R)—1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepin-S- yl)pyrrolidinamine (Compound II-41) FF (8 F O N O) Compound 11-41 was prepared according to Example 19 disclosed herein using the appropriate starting materials. e 58 1-(1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f] [1,4]oxazepin-S-yl)piperidin- 4-yl)pyrrolidinone (Compound 11-42) Compound 11-42 was ed according to Example 19 disclosed herein using the appropriate starting materials.
Example 59 (S)-N-methyl—1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepin-S- yl)pyrrolidinamine (Compound II-44) Compound 11-44 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 60 (S)—N-(1-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo [f] [1,4] oxazepin-S- yl)pyrrolidinyl)pyrimidine—2-carboxamide und 11-45) Compound 11-45 was prepared ing to Example 19 disclosed herein using the appropriate starting materials.
Example 61 (R)—N-(1-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo [f] [1,4] in-S- yl)pyrrolidinyl)pyrimidine—2-carboxamide (Compound 11-46)
[0276] Compound 11-46 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 62 (R)—N-(1-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo [f] [1,4] oxazepin-S- yl)pyrrolidinyl)picolinamide und 11-47) Compound 11-47 was ed according to Example 19 disclosed herein using the appropriate starting materials.
Example 63 (S)—N,N-diethyl—1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepin- 5-yl)pyrrolidinamine (Compound 11-48) Compound 11-48 was prepared ing to Example 19 disclosed herein using the appropriate starting materials. MS m/z 432.1, M+H.
Example 64 1-(naphthalenyloxy)((R)(7-(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4] oxazepinyl)pyrrolidinylamino)propanol (Compound 11- Compound 11-61 was prepared according to e 19 disclosed herein using the appropriate starting materials.
Example 65 (R)—N,N-diethyl—1-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f] [1,4]oxazepin- -yl)pyrrolidinamine (Compound 11-49) Compound 11-49 was prepared according to Example 19 disclosed herein using the appropriate starting materials.
Example 66 N-(pyridinylmethyl)—7-(4-(trifluoromethyl)phenyl)—2,3- obenzo[f] xazepinamine (Compound 11-10) F N\ F0 “N” Compound 11-10 was prepared according to Example 19 disclosed herein using the appropriate starting materials. MS m/z 398.1, M+H, anal HPLC >98%; 1H NMR (400 MHz; DMSO-d6) 5 8.51 (d, J: 4.7 Hz, 1H); 8.20 (s, 1H); 7.96 — 7.75 (m, 7H); 7.45 (d, J: 7.8 Hz, 1H); 7.26 (m, 1H ); 7.20 (d, J: 8.2 Hz, 1H); 4.62 (s, 2H ); 4.37 (m, 2H ); 3.38 (m, 2H). ”P NMR (400 MHz; DMSO-d6) 5 -6l.35 (s, 3F).
Example 67 N-(cyclopropylmethyl)—7—(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine und 11-11)
[0282] Compound 11-11 was prepared according to Example 19 sed herein using the appropriate ng materials. MS m/z 361.1, M+H, anal HPLC >98%; 1H NMR (400 MHz; DMSO-d6) 8 8.51 (s, 1H); 8.15 (m, 3H); 8.07 (m, 3H ); 7.45 (d, J: 8.3 Hz, 1H ); 4.61 (s, 2H); 3.43 (m, 2H); 1.36 (m, 1H ); 0.71 (m, 2H); 0.49 (m, 2H). ”P NMR (400 MHz; DMSO-d6) 8 -60.96 (s, 3F).
Example 68 N-(pyridinyl)—7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f] [1,4]oxazepin amine (Compound 11-19) Compound 11-19 was prepared according to Example 19 sed herein using the appropriate starting materials. MS m/z 384.1, M+H, anal HPLC >95%; 1H NMR (400 MHz; DMSO-d6) 5 8.33 (d, J: 4.7 Hz, 1H); 8.26 (s, 1H ); 8.12 (s, 1H ); 7.92 — 7.80 (m, 6H); 7.70 (m, 1H ); 7.20 (d, J: 8.2 Hz, 1H); 6.99 (m, 1H ); 4.38 (m, 2H); 3.56 (m, 2H ).
”P NMR (400 MHz; DMSO-d6) 5 -6l.37 (s, 3F).
Example 69 N-(2-(pyridinyloxy)ethyl)—7—(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound 11-20) F N00\
[0284] Compound 11-20 was prepared according to Example 19 disclosed herein using the appropriate starting materials. MS m/z 428.1, M+H, anal HPLC >95%; 1H NMR (400 MHz; DMSO-d6) 5 8.26 (s, 1H ); 8.13 (m, 1H); 7.92 — 7.67 (m, 7H ); 7.20 (d, J: 8.6 Hz, 1H ); 6.96 (m, 1H); 6.82 (d, J: 8.6 Hz, 1H); 4.48 (m, 2H ); 4.40 (m, 2H); 3.69 (m, 2H ); 3.43 (m, 2H). ”P NMR (400 MHz; DMSO-d6) 5 -61.36 (s, 3F). e 70 N-(2-phenoxyethyl)—7—(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f] [1,4]oxazepin- -amine (Compound 11-22) : HNNOD O J\N Compound 11-22 was prepared according to Example 19 disclosed herein using the riate starting als. MS m/z 427.1, M+H, anal HPLC >95%; 1H NMR (400 MHz; DMSO-d6) 5 8.16 (s, 1H ); 7.93 — 7.79 (m, 6H); 7.31 — 7.21 (m, 3H); 6.99 — 6.90 (m, 3H); 4.42 (m, 2H); 4.21 (m, 2H); 3.70 (m, 2H); 3.50 (m, 2H). ”P NMR (400 MHz; DMSO-d6) 5 -6l.36 (s, 3F).
Example 71 N-((1-methyl—1H-benzo [d]imidazolyl)methyl)—7-(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] [1,4]oxazepinamine (Compound 11-33) _|.| MN 0 HN\ N O O}
[0286] nd 11-33 was prepared according to Example 19 disclosed herein using the appropriate starting materials. MS m/z 451.1, M+H, anal HPLC >98%; 1H NMR (400 MHz; DMSO-d6) 8 10.53 (s, 1H); 8.11 (d, J: 7.6 Hz, 1H); 8.06 (s, 1H); 7.97 (m, 2H); 7.88 (m, 2H); 7.63 (m, 2H); 7.40 (m, 1H); 7.31 (m, 1H); 7.24 (m, 2H); 5.06 (m, 2H); 4.51 (m, 2H); 3.86 (s, 3H); 3.63 (m, 2H). ”P NMR (400 MHz; DMSO-d6) 5 -61.43 (s, 3F).
Example 72 tert-butyl 4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f] [1,4] oxazepin-S- ylamino)pyrrolidine—l-carboxylate (Compound 11-62) E HN/CNJg/Q
[0287] Compound 11-62 was prepared according to Example 19 disclosed herein using the appropriate starting materials. MS m/z 476.2, M+H, anal HPLC >95%; 1H NMR (400 MHz; 6) 5 10.18 (m, 1H); 9.97 (m, 1H ); 8.10 (d, J: 8.2 Hz, 1H); 7.97 — 7.95 (m, 5H); 7.36 (m, 1H); 4.48 (m, 2H); 4.34 (m, 1H); 3.70 (m, 1H); 3.57 (m, 2H); 2.24 (m, 1H); 2.05 (m, 2H); 1.39 (m, 9H). ”P NMR (400 MHz; DMSO-d6) 5 -61.43 (s, 3F).
Example 73 (S)—tert-butyl 3-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepin-S- ylamino)pyrrolidine-l-carboxylate (Compound II-43)
[0288] Compound 11-43 was prepared according to Example 19 disclosed herein using the appropriate starting als. MS m/z 476.2, M+H, anal HPLC >93%; 1H NMR (400 MHz; DMSO-d6) 5 8.22 (s, 1H); 7.91 (m, 2H); 7.81 (m, 3H); 7.73 (s, 1H); 7.16 (m, 1H); 4.36 (m, 3H); 3.58 — 3.20 (m, 7H); 2.12 (m, 1H); 1.88 (m, 1H); 1.38 (m, 9H). ”P NMR (400 MHz; DMSO-d6) 5 -61.36 (s, 3F).
Example 74 (R)—tert-butyl 3-(7-(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo[f] [1,4] oxazepin-S- ylamino)pyrrolidine—l-carboxylate (Compound II-63) Compound 11-63 was prepared according to Example 19 disclosed herein using the appropriate starting als. MS m/z 476.2, M+H, anal HPLC >95%; 1H NMR (400 MHz; DMSO-d6) 8 8.23 (s, 1H); 7.91 (m, 2H); 7.81 (m, 3H); 7.73 (s, 1H); 7.14 (m, 1H); 4.36 (m, 3H); 3.58 — 3.20 (m, 7H); 2.12 (m, 1H); 1.88 (m, 1H); 1.38 (m, 9H). ”P NMR (400 MHz; DMSO-d6) 8 -61.36 (s, 3F).
The following compounds were prepared ing to the es disclosed herein using the appropriate starting materials: WO 06463 3-methyl(4-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f] [1,2,4]triazolo[4,3- d] [1,4]oxazepine (Compound 1-4) F o w 1 1-(4-(trifluoromethyl)phenyl)—3,4,6,7-tetrahydro-2H-benzo[f] pyrimido[1,2- d] [1,4]oxazepine (Compound 1-8) 3-cyclopropyl(4-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f]imidazo[1,2- d] [1,4]oxazepine (Compound 1-9) 2—(10-(4-(trifluoromethyl)phenyl)-5,6-dihydrobenzo [f] o[1,2-d] [1,4] oxazepin yl)propanol (Compound 1-10) 3-bromo(4-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f]imidazo[1,2- d] [1,4]oxazepine (Compound 1-12) F 0 “r 3-chloro(4-(trifluoromethyl)phenyl)-5,6-dihydrobenzo [f]imidazo[1,2- d] [1,4]oxazepine (Compound I-13) F 0 W -(4-(trifluoromethyl)phenyl)-5,6-dihydrobenzo [f] imidazo[1,2-d] [1,4] oxazepine carbonitrile (Compound I-16) ethyl 10-(4-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f]imidazo[1,2- d] [1,4]oxazepine-Z-carboxylate und I-21) FF O\/ F O N\\ O N OJ 10-(4-(trifluoromethyl)phenyl)-5,6-dihydrobenzo [f] imidazo[1,2-d] [1,4] oxazepine-Z- carboxylic acid (Compound I-22) -(3,3-difluoropyrrolidinyl)(4-(trifluoromethyl)phenyl)—2,3- dihydrobenzo[f] xazepine (Compound II-6) N-phenyl—7—(4-(trifluoromethyl)phenyl)—2,3-dihydrobenzo [f] [1,4] oxazepin-S-amine (Compound II-32) Example 75 Hard gelatin capsules containing the following ingredients are prepared: Quantity Ingredient (mg/capsule) Active Ingredient 30.0 Starch 305.0 Magnesium te 5.0 The above ingredients are mixed and filled into hard n capsules.
Example 76 A tablet Formula Is prepared using the ingredients below: Quantity Ingredient (mg/tablet) Active Ingredient 25.0 Cellulose, microcrystalline 200.0 Colloidal silicon dioxide 10.0 Stearic acid 5.0 The ents are blended and compressed to form tablets.
Example 77 A dry powder inhaler formulation is ed containing the following components: Ingredient Weight % Active Ingredient 5 Lactose 95 The active ingredient is mixed with the lactose and the mixture is added to a dry powder inhaling nce.
Example 78
[0297] Tablets, each containing 30 mg of active ingredient, are prepared as follows: Quantity Ingredient (mg/tablet) Active Ingredient 30.0 mg Starch 45.0 mg Microcrystalline cellulose 35.0 mg Polyvinylpyrrolidone (as 10% on in sterile water) 4.0 mg Sodium carboxymethyl starch 4.5 mg ium stearate 0.5 mg Talc 1.0 mg Total 120 mg The active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50 0C to 60 0C and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each ng 120 mg.
Example 79
[0299] Suppositories, each containing 25 mg of active ingredient are made as follows: Ingredient Amount Active Ingredient 25 mg Saturated fatty acid ides to 2,000 mg The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a itory mold of nominal 2.0 g capacity and allowed to cool.
Example 80 Suspensions, each containing 50 mg of active ingredient per 5.0 mL dose are made as follows: Ingredient Amount Active Ingredient 50.0 mg Xanthan gum 4.0 mg Sodium carboxymethyl cellulose (11%) Microcrystalline cellulose (89%) 50.0 mg Sucrose 1.75 g Sodium benzoate 10.0 mg Flavor and Color q.v.
Purified water to 5 .0 mL
[0302] The active ingredient, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium te, flavor and color are diluted with some of the water and added with stirring.
Sufficient water is then added to produce the required .
Example 81 A subcutaneous formulation may be prepared as follows: Ingredient Quantity Active Ingredient 5.0 mg Corn Oil 1.0 mL e 82 An injectable preparation is prepared having the following composition: Ingredients Amount Active ingredient 2.0 mg/mL Mannitol, USP 50 mg/mL Gluconic acid, USP q.s. (pH 5-6) water (distilled, sterile) q.s. to 1.0 mL Nitrogen Gas, NF q.s.
Example 83 A topical preparation is prepared having the following ition: Ingredients grams Active ingredient 0.2-10 Span 60 2.0 Tween 60 2.0 Mineral oil 5.0 Petrolatum 0.10 Methyl paraben 0.15 Propyl paraben 0.05 BHA (butylated hydroxy anisole) 0.01 Water q.s.t0100 All of the above ingredients, except water, are combined and heated to 60°C with stirring. A sufficient quantity of water at 60°C is then added with vigorous stirring to emulsify the ingredients and water then added q.s. 100 g.
Example 84 Sustained Release Composition Ingredient Weight Range% Active ingredient 50-95 Microcrystalline cellulose (filler) 1-35 Methacrylic acid copolymer 1-35 Sodium hydroxide 0.1-1.0 Hydroxypropyl methylcellulose 0 Magnesium stearate 0.5-5.0 The sustained release ations of this disclosure are ed as follows: compound and pH-dependent binder and any al excipients are intimately mixed(dry-blended). The dry-blended mixture is then granulated in the presence of an aqueous on of a strong base which is sprayed into the blended powder. The ate is dried, screened, mixed with optional lubricants (such as talc or ium te) and compressed into tablets. Preferred aqueous solutions of strong bases are solutions of alkali metal hydroxides, such as sodium or potassium hydroxide, preferably sodium hydroxide, in water (optionally containing up to 25% of water-miscible solvents such as lower alcohols).
The resulting tablets may be coated with an optional film-forming agent, for identification, taste-masking purposes and to improve ease of swallowing. The film forming agent will typically be present in an amount ranging from between 2% and 4% of the tablet weight. Suitable film-forming agents are well known to the art and include hydroxypropyl methylcellulose, cationic rylate copolymers (dimethylaminoethyl rylate/ methyl-butyl methacrylate copolymers - Eudragit® E - Rohm. Pharma) and the like. These film-forming agents may optionally n colorants, plasticizers and other supplemental ingredients.
The compressed tablets preferably have a hardness sufficient to and 8 Kp compression. The tablet size will depend primarily upon the amount of compound in the tablet. The s will include from 300 to 1100 mg of compound free base. Preferably, the tablets will include amounts of compound free base ranging from 400-600 mg, 650-850 mg and 900-1100 mg.
In order to influence the dissolution rate, the time during which the compound containing powder is wet mixed is controlled. Preferably the total powder mix time, i.e. the time during which the powder is exposed to sodium hydroxide solution, will range from 1 to 10 minutes and preferably from 2 to 5 minutes. Following granulation, the particles are removed from the granulator and placed in a fluid bed dryer for drying at about 60°C.
Example 85 Activity testing is conducted in the es below using methods described herein and those well known in the art.
Sodium current screening assays: The late sodium t (Late INa) and peak sodium current (Peak INa) assays are performed on an ted electrophysiology platform, QPatch 16X (Sophion 2012/045021 Bioscience, Copenhagen, Denmark), which uses the whole cell patch clamp que to measure currents through the cell membrane of up to 16 cells at a time. The assay uses an HEK293 (human nic kidney) cell line heterologously expressing the wild-type human cardiac sodium channel, hNaV1.5, purchased from Millipore (Billerica, MA). No beta subunits were coexpressed with the Na channel alpha subunit. Cells are maintained with standard tissue culture ures and stable channel expression is maintained with 400 ug/mL Geneticin in the culture medium. Cells isolated for use on QPatch are incubated for 5 s in Detachin 1X (Genlantis, San Diego, USA) at 37 0C to ensure that 80-90% of the cells are single and not part of a cell cluster. Experiments are carried out at 23-25 0C.
For both the Late INa and Peak INa assays, series resistance compensation is set to 100% and series resistance and whole-cell compensation are med automatically.
Currents are digitized at 25 kHz and low-pass filtered at 12 kHz and 10 kHz for the late and peak INa assays, respectively. Currents through open sodium channels are automatically recorded and stored in the Sophion ence Oracle se on Bioscience, Copenhagen, Denmark). Analysis is performed using QPatch Assay and database software and data are compiled in Excel.
Compound stocks are routinely made by the Gilead Sample Bank in plastic Vials to 10 mM in dimethyl sulfoxide (DMSO). In some cases, when compounds are not soluble in DMSO, they are made in 100% ethanol. Stocks are sonicated as necessary.
The extracellular solution for screening Late INa is ed of: 140 mM NaCl, 4 mM KCl, 1.8 mM CaClz, 0.75 mM MgClz and 5 mM HEPES with pH adjusted to 7.4 using NaOH. The intracellular solution used to perfilse the inside of the cells for both the Late INa and Peak INa assays contains: 120 mM CsF, 20 mM CsCl, 5 mM EGTA, 5 mM HEPES and pH adjusted to 7.4 with CsOH. Compounds are diluted in extracellular solution to 1 uM in glass Vials and then transferred to glass well plates before robotic addition to the cells. A 0 mM Na extracellular solution (0Na-ECF) is used at the end of each experiment for the Late INa and Peak INa assays to measure baseline current contains: 140 mM N—methyl-D-glucamine; 4 mM KCl; 1.8 mM CaC12; 0.75 mM MgC12; 5 mM HEPES and pH was adjusted to 7.4 with HCl.
Late INa Screening Assay: For the hNaVl.5 Late INa assay, sodium channels are activated every 10 seconds (0.1 Hz) by rizing the cell membrane to -20 mV for 250 milliseconds (ms) from a holding potential of -l20 mV. In response to a -20 mV voltage step, typical hNaVl .5 sodium currents activate rapidly to a peak ve current and then inactivate nearly completely within 3-4 ms.
Compounds were tested to determine their activity in blocking the late sodium current. Late INa was generated by adding 10 uM Tefluthrin (pyrethroid) to the extracellular solution while recording Na currents. To confirm the block of late INa observed using the automated ing method, a second late INa enhancer (ATX-II) and the manual patch clamp method were used. ATX-II and rin occupy distinct, non- pping binding sites and modify Na+ channel function differently to increase late INa.
Compounds tested have been found generally to inhibit the enhanced late INa caused by either late INa enhancer. For the purposes of the screening, late INa is defined as the mean t between 225 ms and 250 ms after stepping to -20 mV to activate Na channels.
After ishing the whole cell recording configuration, late INa tor is added to each well 4 times over a 16-17 minute period so that the late component of the Na current reaches a stable value. nds were then added (typically at 1 uM), in the presence of the late INa tor, with 3 ons over the course of 7 or 8 minutes.
Measurements were made at the end of exposure to the third compound on and values were normalized to the current level when all Na+ was removed from the extracellular solution after two additions of ONa-ECF.
Results are reported as percent block of late INa. For example, when tested in the assay sed above with 10 uM Tefluthrin activating late INa, Compound 11-105 inhibited (or reduced) the late sodium current by 45% (see Table l for additional compound data). The inhibition of Late INa of the cardiac isoform hNaV 1.5 support the use of the compounds of this disclosure to treat atrial arrhythmias, ventricular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal’s (variant) angina, stable angina, unstable , exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, pulmonary hypertension and intermittent claudication.
Peak INa ing Assay: Compounds were also evaluated for their effect in several other assays, including their effect on hNaVl .5 Peak INa. Good separation between the concentrations of test compound to reduce late and peak INa is beneficial to enable separation of the desired effect to reduce late INa-induced electrical and mechanical dysfianction from the red effect to reduce peak INa, which can lead to slowing or block of conduction of ical excitation in the heart. It is contemplated that the compounds of Formula I avoid significant block of peak INa. Since the peak INa in the cells used herein can be very large, introducing cts in the recording, the concentration ofNa+ in the bath can be reduced to 20 mM and a nonpermeant cation added to compensate for the Na+ that was removed to maintain the osmolarity and ionic strength of the solution (see solution details below). Analysis of peak INa generally requires correction for rundown before ining the % block of peak current by the tested compound.
A separate Peak INa screening assay was developed to allow assessment of the effect of compounds on peak INa at both low and high stimulation frequencies in order to identify compounds that are highly selective for block of late INa but do not block peak INa. A low stimulation frequency of 0.1 Hz was used to determine the effect of the test compound when the channel spent most of the time in the resting (closed) state and provides information about Tonic Block (TB). A higher ation frequency (3Hz) was used to measure block of the channel when it spent more time in the activated and inactivated states and provided a measure of Use-Dependent Block (UDB). Use- dependent block refers to the accumulation of block with increased frequency of channel activation. Block of cardiac peak INa by nds of this disclosure is increased with an increase in the frequency of stimulation from 0.1 to 1-5 Hz (frequencies tered either in the normal heart or during tachycardia). It is therefore expected that reduction of peak INa by nds of this disclosure will be greater at high heart rates, such as those during tachyarrhythmias, than at normal heart rates. As a consequence, compounds of this sure may reduce Na+ and Ca2+ overload due to late INa and abnormal electrical activity and electrical conduction in myocardium that is arrhythmic, especially during ischemia.
The -lOO mV holding potential and the 3 Hz stimulation frequency were chosen so that the benchmark compound would have a small but able effect under experimental conditions, allowing for direct comparison ofnew compounds with the benchmark. The extracellular solution for screening Peak INa is composed of: 20 mM NaCl, 120 mM N-methyl-D glucamine, 4 mM KCl, 1.8 mM CaClz, 0.75 mM Mng and mM HEPES with pH adjusted to 7.4 using HCl. The intracellular solution used for the Peak INa assay is the same as outlined for the Late INa assay (see above).
For the peak INa assay, Na+ channels were ted by depolarizing the cell membrane to 0 mV for 20 ms from a holding potential of -100 mV. After establishing the whole cell recording configuration, channels were ated to open with low frequency stimulation (0.1 Hz) for 7 minutes so that the recording can be red and the extent to which the recording has stabilized can be ed. After this stabilization period the stimulation frequency was increased to 3 Hz for 2 minutes and then ed to 0.1 Hz.
Since 3 Hz stimulation causes a small decrease in the peak current even in the absence of compound, this internal control was used for each cell, when no compound is t, to correct the results from 3 Hz stimulation when compound is present. Following 3 Hz ation under control conditions, the cell is allowed to r for 200 seconds before compound is added. The test compound tested at l or 3 uM (depending on the % block of late INa at 1 uM) was added 3 times at 60 second intervals, while stimulating the channels to open at 0.1 Hz to monitor the progression of TB. After the third compound addition, a 320 second wait period was imposed to allow for equilibration before the second period of 3 Hz stimulation begins. TB was measured before the second period of 3 Hz stimulation. Both TB and UDB were analyzed by incorporating rundown correction for the peak INa and UDB as calculated by compensating for the small use-dependent effect of the stimulation ol on peak INa in the absence of compound. Compound II-ll exhibited peak INa TB of 11% and peak INa UDB of 31%, both measured at 1 MM.
The above data demonstrates the selectivity of Compound II-ll to block late INa compared to peak INa (41% versus 11% for peak INa TB) which suggests compound II- 11 should have minimal to no effect on electrical conduction h the heart (which is driven by peak INa) at concentrations that effectively block late INa.
Compound II-ll inhibits peak INa UDB at 31% @ luM. This suggests that nd II-ll maybe useful at high heart rates, such as those during tachyarrhythmias, than at normal heart rates. As a consequence, compounds of this disclosure may reduce Na+ and Ca2+ overload due to late INa and abnormal electrical activity and electrical conduction in myocardium that is arrhythmic, especially during ischemia.
Table 1 NAV1.2 UDB- 10HZ* 1 0-(4- (trifluoromethyl)phenyl)— ,6- LN dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 1 0-(4- (trifluorornethoxy)phenyl)- ,6- H 18 dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 1 0-(4- (trifluoromethyl)phenyl)— I-3 5 ,6- dihydrobenzo[f][1 ,2,4]triaz 010[4,3-d] [ 1 ,4]0xazepine 3 l- 1 0-(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[f][1 ,2,4]triaz 010[4,3-d] [ 1 ,4]0xazepine 3 -cyclopropy1—10-(4- (trifluoromethyl)phenyl)— I-5 5 ,6- dihydrobenzo[f][1 ,2,4]triaz 010[4,3-d] [ 1 ,4]0xazepine 3 l- 1 0-(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 3 -(pyrirnidiny1)—10-(4- (trifluoromethyl)phenyl)— I-7 5 ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 1 1-(4- (trifluoromethyl)phenyl)— 3 ,4,6,7-tetrahydr0-2H- benzo[f]pyrirnido[1,2- d][1,4]oxazepine WO 06463 NAV1.2 UDB- 10HZ* 3 -cyclopropy1—10-(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 2-( 1 0-(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepin yl)pr0panol 3 -benzyl(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 3-brorno(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 3-chloro(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 2-ch10r0methyl(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 1 -(1 0-(4- (trifluoromethyl)phenyl)— ,6- obenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepin y1)ethanone 1 0-(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]oxazepine carbonitrile WO 06463 NAV1.2 UDB- 10HZ* 3 -methyl- 1 0-(4- orornethoxy)phenyl)- ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 3 -cyclopropy1—10-(4- (trifluorornethoxy)phenyl) ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine hyl(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 2-cyclopropyl(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine 1 0-(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]oxazepine carboxylic acid 2-(1-methyl-1H-irnidazol- -yl)(4- (trifluoromethyl)phenyl)— ,6- dihydrobenzo[fjirnidazo[ 1 , 2-d][1,4]0xazepine -rnorpholino(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pine N—benzyl(4- (trifluoromethyl)phenyl)— 2,3 - 24 dihydrobenzo[f][1,4]oxaze pin-5 -arnine 2012/045021 NAV1.2 UDB- 10HZ* -(pyrrolidin- 1-y1)(4- (trifluoromethyl)phenyl)— 2,3 - obenzo[f][1,4]oxaze pine N—cyclopropy1(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine N—benzyl-N—rnethyl(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine -(3 ,3 -difluoropyrrolidin y1)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pine N—(pyrimidinylmethyl)— 7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine opropyl-N—rnethyl (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine N—((3-fluoropyridin y1)rnethyl)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine N—(pyridinylrnethyl)—7- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine NAV1.2 N0 UDB- 10HZ* N—(cyclopropylrnethyl) (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine tert-butyl 4- oromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -yl)azetidin-3 - ylcarbarnate (S)—tert-butyl 1-(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrrolidin-3 - ylcarbarnate N—(2-(1H-irnidazol y1)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine (S)—N,N—dirnethyl(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 -arnine (S)-(1-(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrrolidin-3 - y1)rnethanol N—(( 1 -methyl- 1 azol- 2-y1)rnethyl)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine 1 -(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -yl)azetidinamine NAV1.2 N0 UDB- 10HZ* N—(pyridiny1)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine N—(2-(pyridin yloxy)ethyl)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine -(4,4-diflu0r0piperidin y1)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pine N—(2-phenoxyethyl)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine 1 -(7-(4- (trifluoromethyl)phenyl)— 2,3 - obenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 -01 N-(2-(2- chlorophenoxy)ethy1)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine 7-(4- (trifluorornethyl)pheny1)—N— (<6- orornethyl)pyridin y1)rnethyl)-2 ,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine N—( 1 H-tetrazol-S-yl)—7-(4- oromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine 2012/045021 NAV1.2 2c UDB- 10HZ* 7-(4- orornethyl)pheny1)—N— (6-(trifluoromethyl)pyridin- 2-y1)-2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine N—(2,2,2-trifluor0ethyl) (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine 1 -(7-(4- (trifluoromethyl)phenyl)— 2,3 - obenzo[f][1,4]oxaze pinyl)pyrrolidinone -(4-cyclopr0pylpiperaziny1)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pine N—pheny1(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine N—((1-rnethyl- 1H- benzo[d]irnidazol y1)rnethyl)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine N—(l -(pyrirnidin ylmethyl)pyrrolidin-3 -y1)- 7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine NAV1.2 2c UDB- 10HZ* dinyl(3 - (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pinylamin0)pyrrolidin yl)rnethanone -(1,3'-bipyrrolidin-1'-yl)- 7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pine N—(pyrimidinylmethyl)— 1 -(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 -arnine (R)-tert-buty1 methy1(1-(7- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrrolidin-3 - yl)carbamate (R)-N-rnethyl-1 -(7-(4- (trifluoromethyl)phenyl)— 2,3 - obenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 -arnine (S)—tert-butyl methyl(1-(7- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrrolidin-3 - yl)carbamate (R)(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 -arnine NAV1.2 2c UDB- 10HZ* 1 -(1 -(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pinyl)piperidin yl)pyrrolidinone (S)—tert-butyl 3 -(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1arnino)pyrrolidinel-carboxylate (S)—N—rnethyl(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 e (1-<7-<4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrrolidin-3 - yl)pyrirnidine-2 - carboxamide <R)-N—<1-<7—<4— (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrrolidin-3 - yl)pyrirnidine-2 - carboxamide (R)-N-(1-(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrrolidin-3 - yl)pic01inarnide N—diethyl(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 -arnine NAV1.2 N0 UDB- 10HZ* (R)-N,N—diethyl(7-(4- (trifluoromethyl)phenyl)— 2,3 - obenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 -arnine (R)-tert-buty1 1 - (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrrolidin-3 - ylcarbarnate (R)-N,N—dirnethyl(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 -arnine ethylpiperaziny1)- 7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pine (S)—tert-butyl 3-methyl (7-(4- (trifluoromethyl)phenyl)— 2,3 - obenzo[f][1,4]oxaze pin-5 -y1)piperazine-1 - carboxylate N—pheny1(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine -(3 -rnorpholinopyrrolidiny1)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pine <s><7—<4— (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 -arnine NAV1.2 2c UDB- 10HZ* tert-butyl 1-(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 - ylcarbarnate -(2-(pyridin y1)pyrr01idiny1)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pine N—(pyrrolidinyl)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 -arnine -(3 -(pyridin y1)pyrr01idiny1)(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pine 1-(naphthalenyloxy)-3 - ((R)(7-(4- (trifluoromethyl)phenyl)— 2,3 - obenzo[f][1,4]oxaze pin-5 -y1)pyrr01idin-3 - ylamino)propanol tert-butyl 3 -(7-(4- (trifluoromethyl)phenyl)— 2,3 - dihydrobenzo[f][1,4]oxaze pin-5 ino)pyrrolidine- l-carboxylate (R)-tert-buty1 3 -(7-(4- (trifluoromethyl)phenyl)— 2,3 - obenzo[f][1,4]oxaze pin-5 -y1arnino)pyrrolidinel-carboxylate *% Inhibition at 1 MM. 2012/045021 The assay results shown in the above Table establish that compounds tested showed activity as modulators of late sodium current, for example by inhibiting (or ng) the late sodium current.
In some embodiments the effects of a compound of Formula I are specific for the late sodium current and show little or no activity with respect to one or more other ion channels. Thus, in some embodiments, a compound having an activity of reducing late sodium current will also exhibit little or no activity with regard to the peak sodium current.
Example 86 Expression ofhuman Nay/1.1 (DNA All experiments with human NaVl.l are conducted as described (Kahlig, et al., PNAS. 2008, 105: 804). Briefly, expression of hNavl.l is achieved by transient transfection using Qiagen Superfect reagent (5.5 ug ofDNA is transfected at a plasmid mass ratio of 10:1 :1 for (11131132). The human BI and [32 cDNAs are cloned into plasmids containing the marker genes DsRed (DsRed-IRESZ-hBl) or eGFP (eGFP-IRESZ-th) flanking an al me entry site (IRES).
Electrophysiology Whole-cell voltage-clamp recordings are used to measure the biophysical properties ofWT and mutant NaVl .1 channels, as described usly (Kahlig, 2008).
For recording hNavl .l INa, HEK293 cells are superfused with solution containing (in mM): 145 NaCl, 4 KCl, 1.8 CaClz, l MgClz, lO dextrose, lO HEPES, with a pH of 7.35 and osmolarity of 3 10 /kg. The pipette on contains (in mM): 110 CsF, lO NaF, 20 CsCl, 2 EGTA, 10 HEPES, with a pH of 7.35 with an osmolarity of 300 mOsmol/kg. Cells are allowed to stabilize for 10 min after establishment of the whole-cell configuration before current is measured. Series resistance is compensated 90% to assure that the command potential is reached within microseconds with a voltage error <2 mV.
Leak currents are cted by using an online P/4 procedure and all currents are low- pass Bessel ed at 5 kHz and digitized at 50 kHz.
For use-dependent studies, cells are stimulated with depolarizing pulse trains (-lO mV, 5 ms, 300 pulses, 10 and 25Hz) from a holding ial of —120 mV. Currents are then normalized to the peak current recorded in response to the first pulse in each ncy train. For tonic block studies, peak and tent (late) currents are evaluated in response to a 200 ms depolarization to —10 mV (0.2 Hz) following digital ction of currents recorded in the presence and absence of 0.5 uM tetrodotoxin (TTX). The sodium current termed Late INa in the periphery is commonly called persistent INa in the CNS. tent current is calculated during the final 10 ms of the 200 ms step. Data analysis is performed using Clampfit 9.2 (Axon Instruments, Union City, CA, , Excel 2002 (Microsoft, Seattle, WA, U.S.A.), and Pro 7.0 (OriginLab, Northampton, MA, U.S.A) software. s are presented as mean :: SEM.
In vitro Pharmacology
[0329] A stock solution of 10mM compound of Formula I is prepared in 0.1 M HCl or DMSO. A fresh dilution of the compound of Formula I in the bath solution is prepared every mental day and the pH is readjusted to 7.35 as necessary. The final DMSO concentration was kept at 0.1% in all solutions. Direct application of the perfilsion solution to the clamped cell is achieved using the Perfusion Pencil system (Automate, Berkeley, CA). Direct cell perfilsion is driven by gravity at a flow rate of 350 uL/min using a 250 micron tip. This system sequesters the clamped cell within a perfilsion stream and enables complete solution exchange within 1 second. The clamped cell is perfused continuously starting immediately after establishing the whole-cell configuration. Control ts are measured during control solution perfusion. Where appropriate, concentration inhibition curves are fit with the Hill equation: I/Imax = 1/[1+10A(logIC50-I)*k], where IC50 is the concentration that produces half inhibition and k is the Hill slope factor.
Solutions containing the compounds of the disclosure are perfused for three s prior to current recordings to allow equilibrium (tonic) drug block. Tonic block of peak current is measured from this steady-state condition. Use-dependent block of peak current is ed during pulse number 300 of the pulse train, (-10 mV, 5 ms, 300 pulses, 10Hz) from a holding potential of —120 mV. Two sequential pulse train stimulations are averaged to obtain mean current traces for each recording condition.
In vivo pharmacology Jugular vein cannulated male e Dawley rats (250 - 350g, Charles River Laboratories, Hollister, CA) are used to study brain penetration of the compounds of the disclosure in vivo. Animal use is approved by the Institutional Animal Care and Use Committee, Gilead Sciences. Three rats per group are infiased intravenously with the compound of the sure in saline at 85.5 ug/kg/min. After 1, 2.5 or 5 h the s are sacrificed for plasma and brain collection, and concentrations of the compound of the disclosure are measured by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Brain tissue is homogenated in 1% 2N HCl acidified 5% sodium fluoride (final homogenate is diluted 3-fold). Plasma and brain homogenate s (50 ul) are precipitated along with deuterated D3-Formula I as an internal standard, vortexed and centrifuged. The supernatant (50 uL) is transferred and diluted with water (450 ul) prior to injection (10 ul). High performance liquid chromatography was performed using a Shimadzu D liquid chromatograph and a Luna C18(2), 3 um, 20 x 2.0 mm column with a mobile phase consisting of water containing 0.1% formic acid (solution A) and acetonitrile (solution B) carried out under isocratic conditions (75% solution A, 25% solution B; flow rate 0.300 ml/min). Mass spectrometric es are performed using an API3 000 mass spectrometer ed Biosystems, Foster City, CA) operating in positive ion mode with MRM transition 428.1 > 98. Brain-to-plasma ratios are calculated for each sample as ng compound/g brain divided by ng compound/ml plasma.
The compound of Example 1-2 blocked the Nav1.1 channel t by 1% under Chantest conditions at 10Hz at 1uM.
Example 87 Expression ofhuman Nth/1.2 cDNA ype (WT) cDNA stably transfected in Chinese hamster ovary (CHO) cells is used to record INa. Unless otherwise noted, all reagents are purchased from Sigma- Aldrich (St Louis, MO, USA).
Electrophysiology Whole-cell voltage-clamp recordings are used to measure the biophysical ties of WT. , the pipette solution consists of (in mM) 110 CsF, 10 NaF, 20 CsCl, 2 EGTA, 10 HEPES, with a pH of 7.35 and osmolarity of 300 mOsmol/kg. The bath ol) solution contains in (mM): 145 NaCl, 4 KCl, 1.8 CaClz, 1 MgClz, 10 dextrose, 10 HEPES, with a pH of 7.35 and osmolarity of 3 10 mOsmol/kg. Cells are allowed to stabilize for 10 min after establishment of the whole-cell configuration before 2012/045021 current is measured. Series resistance is compensated 90% to assure that the command potential is reached within microseconds with a voltage error <2 mV. Leak currents are subtracted by using an online P/4 procedure and all currents are low-pass Bessel filtered at 5 kHz and digitized at 50 kHz.
For clarity, entative ramp currents are low pass filtered off-line at 50 Hz.
Specific voltage-clamp protocols assessing channel activation, fast inactivation and availability during repetitive stimulation are used. Results are ted as mean :: SEM.
Tonic block of peak current is measured using a step to -10mV (20ms) from a holding potential of -l20mV (0.2Hz). Use-dependent block of peak current is measured during pulse number 300 of a pulse train (—10 mV, 5 ms, 300 pulses, 10Hz or 25Hz) from a holding potential of —l20 mV. ts are then normalized to the peak current recorded in response to the first pulse in each frequency train. For tonic block studies, peak current is evaluated in se to a 20 ms depolarization to —10 mV (0.2 Hz). Two sequential pulse train stimulations are averaged to obtain mean current traces for each recording condition, which are then used for offline subtraction and analysis.
Data analysis is performed using Clampfit 9.2 (Axon Instruments, Union City, CA, USA), Excel 2002 (Microsoft, Seattle, WA, USA), and OriginPro 7.0 (OriginLab, Northampton, MA, USA) software. Results are presented as mean :: SEM.
In vitro Pharmacology
[0338] A stock solution of 10mM compound of a I is prepared in 0.1 M HCl or DMSO. A fresh dilution of the compound of Formula I in the bath solution is prepared every experimental day and the pH is readjusted to 7.35 as ary. The final DMSO concentration was kept at 0.1% in all solutions. Direct application of the perfilsion solution to the clamped cell is ed using the Perfusion Pencil system ate, Berkeley, CA). Direct cell perfilsion is driven by gravity at a flow rate of 350 uL/min using a 250 micron tip. This system sequesters the d cell within a perfilsion stream and enables complete solution exchange within 1 second. The clamped cell is perfused continuously starting immediately after establishing the cell configuration. Control currents are measured during control solution perfusion.
[0339] Solutions are perfused for three minutes prior to current recordings to allow equilibrium ) drug block. Tonic block of peak currents is measured from this steady-state condition. Three sequential current traces are averaged to obtain a mean current for each recording. The mean current traces are utilized for offline analysis.
Where appropriate, tration inhibition curves are fit with the Hill on: I/Imax = OA(logIC50-I)*k], where IC50 is the concentration that produces half inhibition and k is the Hill slope factor.
Using the above s it may be trated that the compounds of the disclosure are selective for inhibiting cardiac Late INa current without inhibiting peak and low frequency currents of brain isoforms NaVl .l and Navl .2. The nds of the disclosure may inhibit the very high frequency firing of NaVl .l and NaVl .2 or demonstrate voltage dependent block of mutant NaVl .l and Navl .2 observed with epilepsy ts. In addition compounds of this disclosure may show activity for inhibition of a panel ofNa- V1.1 mutant channels associated with the epilepsy and headache (migraine) syndromes GEFS+, SMEI and FHM3 suggesting the ability of the nds of the disclosure to preferentially block the abnormal increased persistent current carried by these mutant channels.
When tested in the assay disclosed above for hNaVl .2 sodium channel isoforms, the compound of Example 1-2 blocked the NaVl .2 channel current by 18% under Chantest conditions at lOHz at 1 uM. The inhibition of either hNaVl.l and hNaVl .2 isoforms or the inhibition of both channels when stimulated at these frequencies support the use of compounds of this disclosure to treat patients with epilepsy. 1001357339

Claims (15)

CLAIMS 1.:
1. A compound of Formula I: 5 wherein: -Y-Z— is —C(:NR4)~NR2— or -C(NR5R6)=N—; R1 is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; wherein said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are ally substituted with one, two or three substituents ndently selected 10 from the group consisting of halo, —NOg, —CN, —SF5, —Si(Cl~l3)3, —O—R20, ~S—R20, -C(O)—R20, —C(O)—OR20, —N(R20)(R22), —C(O)-N(R2°)(R22), —N(R20)—C(O)« R22, —N(R20)-C(O)—OR22, —N(R20)—S(=O)2—R26, ~S(:O)2—R20, -o—S(:O)2—R20, —S(=O)2—N(R20)(R22), (3., alkyl, C2.4 l, C2.4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and 15 wherein said C1-6 alkyl, C24 alkenyl, C24 l, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents ndently selected from the group consisting of halo, —N02, phenyl, cyclyl, heteroaryl, CH, alkyl, cycloalkyl, —N(R20)(R22), -C(O)—R2°, —C(O)—OR20, ~C(O)—N(R2°)(R22), ~CN and ~o— 20 R20; R2 is hydrogen, C1.6 alkyl, —C(O)—R20, -C(O)—OR26, —C(O)~N(R26)(R26), —N(R20)—S(:O)z— R20, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are ally substituted with one, two or three substituents independently selected from the 25 group consisting of C1_6 alkyl, C2_4 alkynyl, halo, ~N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, ~N(R20)(R22), —C(O)-R20, -C(O)—OR2°, {3(0)- N(R20)(R22), -CN, oxo and -O-R20; 1001357339 wherein said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, CM alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)—R20, -C(O)- 5 0R”, -C(O)—N(R2°)(R22), -CN and -O-R20; and wherein said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group ting of halo, —N02, —CF3, )(R22), -C(O)—R20, —C(O)-OR20, 10 ~C(O)—N(R20)(R22), ~CN, —S(O)2~R20 and —O—R20; nisO, 1,2,3 or4; each R3 is ndently CH, alkyl, lkyl, aryl, heteroaryl or heterocyclyl; wherein said CH, alkyl is optionally substituted with one, two or three substituents independently selected from the group ting of halo, —N02, cycloalkyl, aryl, 15 heterocyclyl, heteroaryl, -N(R20)(R22), —C(O)—R20, -C(O)—OR20, -C(O)— N(R2O)(R22), —CN and on”; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally r substituted with one, two or three substituents independently ed from the group consisting of halo, —N02, CH, alkyl, aralkyl, 2O cycloalkyl, aryl, cyclyl, heteroaryl, -N(R20)(R22), —C(O)—l{20, ~C(O)—OR2°, -C(O)-N(R20)(R22), —CN and OR”; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of 25 halo, —Noz, -N(R20)(R22), —C(O)—R20, —C(O)—OR2°, —C(O)—N(R2°)(R22), -CN and OR”; or two R3 ed to a common carbon atom form an oxo; or two R3 attached to a common or adjacent carbon atoms form a cycloalkyl or heterocyclyl; 1001357339 wherein said cycloalkyl or cyclyl are optionally further tuted with one, two or three substituents independently selected from the group consisting of halo, —N02, C1-6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)—R20, —C(O)-OR2°, —C(O)-N(R20)(R22), -CN and -O-R20; 5 R4 is C1-6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1-6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, —N02, cycloalkyl, aryl, heterocyclyl, aryl, —N(R20)(R22), R20, ~C(O)—OR20, —C(O)—N(R2°)(R22), —CN and —O-R20; 1O wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally r substituted with one, two or three substituents independently selected from the group consisting of halo, ~NOZ, (31-6 alkyl, aralkyl, cycloalkyl, aryl, cyclyl, heteroaryl, -N(R20)(R22), —C(O)—R20, —C(O)—OR2O, —C(O)—N(R20)(R22), —CN and 0—1120; and 15 n said C|_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently ed from the group consisting of hydroxyl, halo, —N02, —N(R2°)(R22), —C(O)—R20, —C(O)—OR20, —C(O)—N(R20)(R22), —CN and ; 20 or R2 and R4 can join together with the atom to which they are attached to form a cyclyl or heteroaryl; n said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, C1_6 alkyl, cycloalkyl, heteroaryl, -CN, —O~R20, —N(R20)(R22), —C(O)-R20, 25 -N(R20)—C(O)—OR20 and -C(O)~OR20; and wherein said CM alkyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -CN, —O-R20, C1_6 alkyl, aryl, and heteroaryl; R5 is hydrogen, CM alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; 1001357339 wherein said C1-6 alkyl, eycloalkyl, aryl, heteroaryl or heteroeyclyl are optionally substituted with one, two or three substituents independently ed from the group consisting of halo, -NOz, cycloalkyl, aryl, heteroeyclyl, heteroaryl, -N(R2°)(R22), —C(O)—R20, ~C(O)—OR20, -C(O)—N(R2°)(R22), -CN and —O-R20; 5 wherein said cycloalkyl, aryl, heteroeyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, —N02, CM alkyl, aralkyl, eyeloalkyl, aryl, heteroeyclyl, heteroaryl, —N(R20)(R22), -C(O)-R20, —C(O)—OR2°, ~C(O)—N(R20)(R22), —CN and 0-11”; and 10 wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heteroeyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, —NOZ, —N(R20)(R22), R20, —C(O)—OR20; R6 is CH, alkyl, cycloalkyl, aryl, heteroaryl or heteroeyclyl; 15 wherein said C 1-6 alkyl, eyeloalkyl, aryl, aryl or eyclyl are optionally substituted with one, two or three substituents ndently selected from the group ting of halo, ~NOz, C14, alkyl, cycloalkyl, aryl, heteroeyclyl, heteroaryl, -N(R20)(R22), —C(O)~R20, —C(O)—OR20, -C(O)—N(R20)(R22), —CN and —0- R20; 20 wherein said CH, alkyl, cycloalkyl, aryl, heteroeyclyl or heteroaryl are optionally further tuted with one, two or three substituents independently selected from the group consisting of halo, —N02, CH, alkyl, aralkyl, eyeloalkyl, aryl, heteroeyclyl, heteroaryl, ~N(R20)(R22), R20, —C(O)—OR20, —C(O)-N(R2°)(R22), —CN and -O—R20; and 25 wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, eyclyl or heteroaryl are ally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R20)(R22), —C(O)-R20, -C(O)-OR2°; or R5 and R6 can join together with the atom to which they are attached to form a 30 heteroeyclyl or heteroaryl; 1001357339 wherein said heterocyclyl or heteroaryl is ally substituted with one, two or three substituents independently selected from the group consisting of halo, C1-5 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, 0X0, -CN, -O-R20, -N(R20)(R22), )-C(O)-R2°, —N(R2°)-C(O)-OR20 and OR2°; and 5 wherein said C1_6 alkyl or heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 0X0, heteroaryl and —O-R20; R20 and R22 are in each instance independently selected from the group ting of hydrogen, C1_6 alkyl, cycloalkyl, cyclyl, aryl and heteroaryl; and 10 wherein the C1-6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C1_4 alkyl, acylamino, oxo, —N02, -SOZR26, —CN, C1_3 alkoxy, aryloxy, —CF3, —OCF3, —OCH2CF3, —C(O)—NH2, aryl, cycloalkyl and heteroaryl; 15 wherein said heteroaryl is optionally further substituted with C14 alkyl or cycloalkyl; or when R20 and R22 are attached to a common nitrogen atom R20 and R22 may join to form a heterocyclyl or aryl which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, 20 C1_4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, —N02, -SOzR26, —CN, C13 alkoxy, —CF3, —OCF3, aryl, heteroaryl and cycloalkyl; and each R26 is independently selected from the group ting of hydrogen, C14 alkyl, aryl and cycloalkyl; wherein the C14 alkyl, aryl and cycloalkyl may be fiirther substituted with from 1 25 to 3 substituents independently selected from the group ting of hydroxyl, halo, C14 alkoxy, -CF3 and -OCF3; or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer f; provided that when R2 and R4 join together with the atom to which they are attached to form an ally substituted imidazolyl, the imidazolyl it is not directly 3O substituted with an optionally substituted lyl, or R1 is not optionally substituted pyrazolyl, 2-pyridinonyl or 2—fluoropyridinyl. 1 3 7 1001357339
2. A compound according to claim 1, wherein the compound has a ure according to Formula IA: N/ 2 \ NF R1—:— > / OJ\(R3)n wherein: R1 is aryl, cycloalkyl, lkenyl, heterocyclyl or heteroaryl; wherein said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting ofhalo, —N02, —CN, —SF5, g)3, ~O—R20, —S—R20, 1O -C(O)—R20, -C(O)—OR2°, ~N(R20)(R22), N(R2°)(R22), —N(R20)—C(O)—R22, —N(R2°)—C(O)-OR22, —N(R20)—S(:O)2-R26, -S(:O)2-R20, —O—S(=O)2—R20, —S(=O)2—N(R2”)(R22), CH, alkyl, C2.4 alkenyl, (32.4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said CH, alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, 15 aryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting ofhalo, —N02, phenyl, cyclyl, heteroaryl, CH, alkyl, cycloalkyl, — N(R20)(R22), —C(O)—R20, —C(O)—OR20, —C(O)—N(R2°)(R22), —CN and on”; R2 is en, (31-6 alkyl, ~C(O)—R20, —C(O)—OR26, -C(O)—N(R26)(R26), —N(R20)—S(:O)2— 20 R20, cycloalkyl, aryl, aryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently ed from the group consisting of C1-6 alkyl, C24 alkynyl, halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R2°)(R22), -C(O)—R20, -C(O)—OR2°, -C(O)- 25 (R22), -CN, 0x0 and -O-R2°; wherein said Cm alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, —NOz, C1_6 alkyl, 1 3 8 1001357339 cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), —C(O)-R20, -C(O)— ORZO, -C(O)—N(R2°)(R22), -CN and -O-R2°; and wherein said CH, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three tuents independently selected from the group consisting of halo, —NOZ, ~CF3, )(R22), -C(O)—R20, —C(O)—OR2°, -C(O)-N(R2°)(R22), -CN, -S(O)2-R2° and OR”; nis 0, 1,2, 3 or4; each R3 is independently CM alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; ’IO wherein said CM, alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -NOz, cycloalkyl, aryl, heterocyclyl, heteroaryl, —N(R20)(R22), —C(O)—R20, —C(O)-OR20, —C(O)-N(R20)(R22), —CN and OR”; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally 15 further substituted with one, two or three substituents independently selected from the group consisting of halo, *NOZ, CH, alkyl, aralkyl, cycloalkyl, aryl, cyclyl, heteroaryl, —N(R20)(R22), ~C(O)—R20, —C(O)—OR20, —C(O)—N(R20)(R22), ~CN and on”; and wherein said CM alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or 20 aryl, are ally further substituted with one, two or three substituents independently selected from the group ting of halo, —N02, )(R22), —C(O)-R2°, —C(O)—OR20, —C(O)—N(R20)(R22), ~CN and OR”; or two R3 attached to a common carbon atom form an OX0; 25 or two R3 attached to a common or adjacent carbon atoms form a cycloalkyl or heterocyclyl; n said cycloalkyl or heterocyclyl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, 30 -N(R20)(R22), —C(O)-R20, -C(O)—OR2°, N(R2°)(R22), —CN and -O-R2°; 1001357339 R4 is C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, —N(R20)(R22), -C(O)—R2°, —C(O)—OR2°, N(R2O)(R22), -CN and OR”; n said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, C1-6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, ~N(R20)(R22), —C(O)—R20, 1O —C(O)—OR20, —C(O)—N(R20)(R22), —CN and —O-R20; and wherein said CH, alkyl, aralkyl, cycloalkyl, aryl, cyclyl or heteroaryl are optionally further substituted with one, two or three substituents ndently selected from the group consisting of hydroxyl, halo, —N02, -N(R20)(R22), —C(O)—R20, -C(O)—OR20, 15 —C(O)-N(R20)(R22), —CN and —()—R20; or R2 and R4 can join together with the atom to which they are attached to form heterocyclyl or aryl; wherein said cyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group ting of halo, CH, 20 alkyl, cycloalkyl, heteroaryl, ~CN, on”, )(R22), —C(O)—R20, -N(R20)-C(O)—()R20 and —C(O)—OR20; and wherein said CH, alkyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, —CN, —O—R20, C1_6 alkyl, aryl, and heteroaryl; 25 R20 and R22 are in each instance independently selected from the group consisting of hydrogen, CH, alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and n the CM alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C1_4 alkyl, acylamino, oxo, -N02, —SOzR26, 30 -CN, C13 alkoxy, aryloxy, ~CF3, -OCF3, -OCH2CF3, NH2, aryl, lkyl and heteroaryl; l 40 1001357339 wherein said heteroaryl is optionally further substituted with C14 alkyl or cycloalkyl; or when R20 and R22 are ed to a common nitrogen atom R20 and R22 may join to form a heterocyclyl or heteroaryl which is then ally tuted with one, two or three 5 substituents independently selected from the group consisting of hydroxyl, halo, C1_4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, —N02, ~SOzR26, —CN, C14; alkoxy, ~CF3, —OCF3, aryl, heteroaryl and cycloalkyl; and each R26 is independently selected from the group consisting of hydrogen, C14 alkyl, aryl and cycloalkyl; 10 wherein the CM alkyl, aryl and cycloalkyl may be r substituted with from 1 to 3 substituents ndently selected from the group consisting ofhydroxyl, halo, C1_4 alkoxy, CE and ~OCF3; or a ceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof; provided that when R2 and R4 join together with the atom to which they are 15 attached to form an optionally substituted imidazolyl, the imidazolyl it is not directly tuted with an optionally substituted triazolyl, or R1 is not optionally substituted pyrazolyl, 2-pyridinonyl or 2—l‘luoropyridinyl.
3. The compound of claim 2, wherein: R1 is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; 20 wherein said aryl, cycloalkyl, lkcnyl, heterocyclyl or heteroaryl are optionally substituted with one, two or three substituents independently ed from the group consisting of halo, -NOz, —CN, —SF5, —Si(CH3)3, —O—R20, -S—R2°, —C(O)—R20, -C(O)—OR20, —N(R2°)(R22), —C(O)—N(R20)(R22), —N(R20)—C(O)—R22, -N(R20)—C(O)—OR22, )~S(=O)2-R26, -S(=O)2-R20, -O—S(=O)2—R20, 25 ~S(=O)2-N(R20)(R22), CH, alkyl, (32.4 l, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1-6 alkyl, C2_4 alkenyl, C2-4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 30 -N02, phenyl, heterocyclyl, heteroaryl, C1-6 alkyl, cycloalkyl, 7339 —N(R2°)(R22), —C(O)-R20, OR2°, —C(O)-N(R2°)(R22), -CN and —0— R20; n is 0; and R2 and R4 join together with the atom to which they are attached to form a heterocyclyl or 5 heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, C16 alkyl, cycloalkyl, heteroaryl, —CN, ~O—R20, -N(R20)(R22), R20, )— C(0)—OR20 and —C(O)—OR20; and 10 wherein said Cm alkyl or aryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, —CN, —O—R20, CH, alkyl, aryl, and heteroaryl.
4. The compound of claim 2, wherein: R] is aryl; 15 wherein said aryl is optionally substituted with one, two or three substituents independently selected from the group consisting ofhalo, ~N02, —CN, -SF5, —Si(CHg)3, -0412", —S—R20, —C(O)—R20, —C(O)—OR2°, —N(R2°)(R22), —C(O)- R”), -N(R2">—C(O)-R22, —N(R20)-C(O)—OR22, -N<R20>—S<:0>2-R2°, —S(=O)2—R20, —O—S(=O)2—R20, —S(=O)2-N(R20)(R22), C1_(,a1kyl, C2.4 alkenyl, 20 C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said CH, alkyl, C24 l, C24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently ed from the group ting of halo, —N02, phenyl, heterocyclyl, heteroaryl, CH) alkyl, cycloalkyl, 25 -N(R20)(R22), —C(O)-R2°, —C(O)—OR20, —C(O)-N(R20)(R22), -CN and -O—R20; n is 0; and R2 and R4 join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; 1001357339 wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, C14, alkyl, lkyl, heteroaryl, -CN, -O~R20, —N(R2°)(R22), -C(O)~R20, —N(R2°)-C(O)-OR2° and —C(O)-OR7’°; and wherein said C1_6 alkyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, ~CN, ~O-R20, C1_6 alkyl, aryl, and heteroaryl.
5. The nd of claim 2, wherein: R1 20 is aryl optionally substituted with ~O—R or C1_6 alkyl; and 1O wherein said CM alkyl is optionally substituted with one, two or three halo; n is 0; R2 and R4 join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or 15 three substituents independently ed from the group consisting , (31.6 alkyl, cycloalkyl, heteroaryl, cm on”, —N(R20)(R22), —C(O)—R20, -N(R2°)—C(O)—OR2° and —C(O)—OR20; and wherein said CM alkyl or heteroaryl are ally substituted with one, two or three substituents independently selected from the group consisting 20 of halo, —CN, -O—R20, C1_6 alkyl, aryl, and heteroaryl.
The nd of claim 2, wherein: R1 is phenyl substituted with ~O-CF3 or -CF3; n is O; and R2 and R4 join together with the atom to which they are attached to form a heterocyclyl or 25 heteroaryl; wherein said heterocyclyl or heteroaryl is ally substituted with one, two or three substituents independently selected from the group consisting of halo, C1.6 alkyl, cycloalkyl, heteroaryl, —CN, -C(O)—R2°, -N(R2°)—C(O)-OR2° and -C(O)—OR2°; and 1001357339 n said C1-6 alkyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -CN, -O-R20, C1_6 alkyl, aryl, and aryl.
7. A compound selected from the group ting of: 3-cyclopropyl—1 0—(4—(trifluoromethyl)phenyl)—5,6- dihydrobenzo[fj [1 ,2,4]triazolo[4,3-d] [1 ,4]oxazepine; 3 —rnethyl—10—(4—(trifluoromethyl)phenyl)-5,6—dihydrobenzo[flimidaon ,2— d][1 ,4]oxazepine; 3-(pyrimidin—2—yl)— l 0—(4-(trifluoromethyl)phenyl)—5 ,6~dihydrobenzo[flimidazo [l ,2— ]oxazepine; and 3—cyclopropyl—l O—(4—(trifluoromethoxy)phcnyl)~5,6—dihydrobenzo[flimidazofl ,2— d] [l ,4]oxazepine; or a pharmaceutically acceptable salt, stcreoisomer, mixture of stereoisomcrs, or tautomer, thereof.
8. A compound according to claim 1, wherein the compound has a structure according to Formula lB: R5\N’ / l 3 10 O// (R )n wherein: R1 is aryl, lkyl, cycloalkenyl, heterocyclyl or aryl; wherein said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are 15 optionally substituted with one, two or three substituents independently selected from the group consisting of halo, —NOZ, -CN, -SF5, -Si(CH3)3, —O-R2°, -S-R20, -C<0>~R2°, -c<0>-OR2°, -N(R2°)<R22), -C(O)—N(R2°)(R22), -N(R20)-C(O)-R22, -N(R2°)—C(O)-OR22, ~N(R2°)-S(=O)2-R26, —S(=O)2—R20, ~O—S(=O)2-R20, —S(=O)2—N(R20)(R22), CH, alkyl, C24 l, C2-4 alkynyl, cycloalkyl, aryl, 20 heteroaryl and heterocyclyl; and 1001357339 wherein said C1-6 alkyl, C24 alkenyl, C2_4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are ally substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, phenyl, heterocyclyl, heteroaryl, C14, alkyl, cycloalkyl, 5 ~N(R2°)(R22), —C(O)—R20, -C(O)-OR2°, —C(O)-N(R20)(R22), —CN and -O-R20; nis 0, 1,2, 3 or4; each R3 is independently CH; alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; n said C1_6 alkyl is optionally substituted with one, two or three substituents 10 independently selected from the group consisting of halo, —N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, —N(R20)(R22), —C(O)—R20, —C(O)—OR20, —C(O)- N(R20)(R22), -CN and OR”; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further tuted with one, two or three substituents independently 15 selected from the group consisting of halo, -N02, CH, alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, —N(R20)(R22), —C(O)—R20, ~C(O)~OR20, —C(O)—N(R20)(R22), ~CN and on”; and wherein said CM alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or aryl, are optionally r tuted with one, two or three 20 substituents independently selected from the group consisting of halo, —N02, —N(R20)(R22), -C(O)—R20, OR2°, —C(O)— N(R20)(R22), —CN and 0—11”; or two R attached to a common carbon atom form an 0x0; or two R3 attached to a common or nt carbon atoms form a cycloalkyl or 25 heterocyclyl; wherein said cycloalkyl or heterocyclyl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, —N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R2°)(R22), -C(O)-R20, -C(O)—OR20, N(R2°)(R22), -CN and "; 30 R5 is hydrogen, (31.6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; 1001357339 wherein said C1-6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are ally tuted with one, two or three substituents independently selected from the group consisting of halo, —N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), —C(O)—R2°, —C(O)—OR2°, -C(O)—N(R20)(R22), —CN and -O-R2°; 5 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents ndently ed from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)—R20, ~C(O)—OR2°, —C(O)-N(R20)(R22), —CN and —O-R2°; and 10 wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of yl, halo, ~Noz, —N(R20)(R22), —C(O)—R2°, -C(O)-OR20; R6 is CH, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; 15 wherein said CH, alkyl, lkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, ~NO2, C14, alkyl, lkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), R20, —C(O)-OR20, -C(O)~N(R20)(R22), -CN and —o— R20; 20 wherein said CH, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, —N02, CH, alkyl, aralkyl, cycloalkyl, aryl, cyclyl, heteroaryl, )(R22), —C(O)—R20, —C(O)—OR20, —C(O)—N(R20)(R22), -CN and -O—R2°; and 25 wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally r substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R20)(R22), -C(O)-R2°, —C(O)-OR2°; or R5 and R6 can join together with the atom to which they are attached to form a 30 heterocyclyl or heteroaryl; 1001357339 wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents ndently selected from the group consisting of halo, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, 0X0, —CN, —O-R2°, —N(R20)(R22), —N(R20)-C(O)-R20, -N(R20)-C(O)—OR2° and -C(O)-OR2°; and 5 wherein said C1.6 alkyl or heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, heteroaryl and -O-R20; R20 and R22 are in each instance independently selected from the group consisting of hydrogen, C1_6 alkyl, cycloalkyl, cyclyl, aryl and heteroaryl; and 10 wherein the CH, alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally tuted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C1_4 alkyl, ino, oxo, —N02, 6021126, -CN, C1_3 alkoxy, aryloxy, ~CF3, —OCF3, —OCHZCF3, —C(O)—NHz, aryl, cycloalkyl and heteroaryl; 15 wherein said heteroaryl is ally further substituted with CM alkyl or cycloalkyl; or when R20 and R22 are attached to a common nitrogen atom R20 and R22 may join to form a heterocyclyl or heteroaryl which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, 20 CM alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, —N023 —SOgR26, ~CN, CH; alkoxy, *CF3, ~OCF3, aryl, heteroaryl and cycloalkyl; and each R26 is independently selected from the group consisting of hydrogen, CM alkyl, aryl and cycloalkyl; wherein the (31-4 alkyl, aryl and cycloalkyl may be r substituted with from 1 25 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C1-4 alkoxy, -CF3 and ~OCF3; or a pharrnaceutically acceptable salt stereoisomer, mixture of isomers, or tautomer f.
9. The compound of claim 8, wherein: 30 R1 is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; 1001357339 wherein said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group ting of halo, -NOZ, —CN, -SF5, -Si(CH3)3, -O—R20, —S-R20, —C(O)-R2°, -C(O)-OR2°, -N(R2°)(R22), -C(O)-N(R20)(R22), —N(R20)-C(O)-R22, 5 -N(R2°)—C(O)-OR22, -N(R2°)—S(=O)2-R26, 2-R20, —O—S(=O)2-R2°, 2— (R22), c1.6 alkyl, CM alkenyl, (32-4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1_6 alkyl, C24 alkenyl, CM alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three 10 substituents independently selected from the group consisting of halo, —N02, phenyl, heterocyclyl, heteroaryl, C1-6 alkyl, cycloalkyl, —N(R2”)(R22), —C(O)—R20, ~C(O)—OR2°, —C(())—N(R20)(R22), ~CN and —0— R20; n is 0; 15 R5 is hydrogen or CH, alkyl; and R6 is CH, alkyl, lkyl, aryl, heteroaryl or heterocyclyl; wherein said C14, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, —N02, CM alkyl, cycloalkyl, aryl, heterocyclyl, 20 heteroaryl, —N(R20)(R22), —C(O)—R2°, -C(O)—OR2°, ~C(O)—N(R20)(R22), —CN and on”; wherein said C1_5 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, —N02, (31-6 alkyl, 25 aralkyl, lkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, —C(O)-OR2°, -C(O)—N(R20)(R22), —CN and ; and n said C1-6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents ndently selected from the group consisting of 30 hydroxyl, halo, —NOz, —N(R20)(R22), -C(O)-R20, -C(O)-OR20; 1001357339 or R5 and R6 can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three tuents ndently selected from the group consisting of halo, C1-6 alkyl, cycloalkyl, cyclyl, aryl, heteroaryl, oxo, -CN, —O—R20, -N(R2°)(R22), -N(R2°)—C(O)—R20, )-C(O)-OR20 and ~C(O)-OR2°; and n said C1_6 alkyl or heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, heteroaryl and ~O—R20. 10 10. The compound ofclaini 8, wherein: R1 is aryl; wherein said aryl is optionally tuted with one, two or three substituents independently selected from the group consisting of halo, —N02, —CN, —SF5, -Si<CH3)3, 0—K”, -s-R2", -C(O)-R20, —C(O)—OR20, —N<R20)<R”>, -C<0>— 15 N<R2°><R22t —N<R2°>—C<O>—R2€ —N(R20)—C(O)—OR22, )-S(=0>2—R26, —S(=O)2—R20, —o—S(:O)2—R2°, —S(=O)2—N(R20)(R22), (31-6 alkyl, C2.4 alkenyl, (32.4 l, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C14, alkyl, C24 alkenyl, CM alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three 20 substituents independently selected from the group consisting ofhalo, —N02, phenyl, heterocyclyl, heteroaryl, C1_6 alkyl, cycloalkyl, — N(R20)(R22), —C(O)—R20, —C(O)—OR20, -C(O)—N(R20)(R22), —CN and OR”; n is 0; R5 is hydrogen or C1_6 alkyl; and 25 R6 is CH5 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1-6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, ~N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, aryl, -N(R2°)(R22), -C(O)-R20, OR2°, -C(O)-N(R20)(R22), —CN and 30 —O—R20; 1001357339 wherein said C1-6 alkyl, cycloalkyl, aryl, cyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NOZ, C1-6 alkyl, l, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), —C(O)-R20, 5 -C(O)-OR2°, —C(O)-N(R2°)(R22), -CN and -O—R2°; and wherein said C1-6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group ting of hydroxyl, halo, «N02, —N(R2O)(R22), —C(O)—R20, —C(O)—OR2°;
10 or R5 and R6 can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, CH, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, —CN, —O—R20, —N(R20)(R22), 15 )—C(O)—R20, -N(R20)—C(O)—OR2O and can—0112"; and wherein said CH, alkyl or heterocyclyl is ally substituted with one, two or three substituents independently ed from the group consisting ol‘ halo, oxo, heteroaryl and —O—R20.
ll. The compound ofclaim 8, wherein: 20 R1 is aryl optionally substituted with —O—R or CH, alkyl; and wherein said CH, alkyl is optionally substituted with one, two or three halo; n is O; R5 is hydrogen or CH, alkyl; and R6 is CH5 alkyl, lkyl, aryl, heteroaryl or heterocyclyl; 25 wherein said CH3 alkyl, cycloalkyl, aryl, heteroaryl or cyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, —N02, C1_6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R2°)(R22), -C(O)-R2°, -C(O)-OR2°, —C(O)-N(R20)(R22), -CN and -O-R20; 1001357339 wherein said C1_6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are ally r substituted with one, two or three substituents independently ed from the group consisting of halo, -N02, C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), -C(O)-R20, 5 ~C(O)—OR2°, -C(O)-N(R20)(R22), —CN and -O-R20; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, —N02, -N(R20)(R22), —C(O)—R20, —C(O)-OR20; 10 or R5 and R6 can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents ndently ed from the group consisting of halo, C1_6 alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, —CN, —O-R20, -N(R20)(R22), 15 —N(R2°)—C(O)-R20, —N(R20)-C(O)—OR2° and —C(O)-OR20; and wherein said CM alkyl or heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, heteroaryl and —O—R2O.
12. The compound of claim 8, wherein: 20 R1 is phenyl substituted with —O—CF3 or CE; n is O; R5 is hydrogen or (31-6 alkyl; and R6 is (31-6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1_6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally 25 substituted with one, two or three tuents ndently selected from the group consisting of halo, -N02, C1-6 alkyl, lkyl, aryl, heterocyclyl, heteroaryl, -N(R2°)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R2°)(R22), -CN and o R20; wherein said C1-5 alkyl, lkyl, aryl, heterocyclyl or aryl are 30 optionally further substituted with one, two or three substituents 1001357339 independently selected from the group consisting of halo, -N02, CH, alkyl, l, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R22), —C(O)—R20, -C(O)—OR2°, -C(O)—N(R2°)(R22), -CN and -O-R2°; and wherein said C1_6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -N02, -N(R2°)(R22), —C(O)-R20, -C(O)—OR2°; or R5 and R6 can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; 1O wherein said heterocyclyl or heteroaryl is optionally substituted with one, two or three substituents independently selected from the group ting ofhalo, CH) alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, 0X0, ~CN, —O—R20, —N(R20)(R22), —N(R20)—C(O)—R20, —N(R2°)—C(O)-OR20 and —C(O)—OR20; and wherein said C1_6 alkyl or heterocyclyl is ally substituted with one, 15 two or three substituents independently ed from the group consisting of halo, oxo, heteroaryl and ~O—R20.
13. The compound of claim 8, n the groups R5 and R6 combine with the nitrogen atom to which they are attached to form a heterocyclyl group selected from the group consisting of 1001357339 HN)L HN//<Jr (341% 4’ (54*HNJ< 44’4o45%Nooo 5 and wherein the point of attachment to the ine ring is at the bivalent nitrogen atom as drawn.
14. The compound of claim I, wherein R2 and R4 join together with the atom to which they are attached to form a cyclyl or heteroaryl selected from the group consisting of [D a’firm ENLWBr 14/ “Dr 14> my 73w,N N ,N N N ,N.N M, w,'wflw,4‘~w, N‘w O O OH 0 D/“D’tN\:N N\\ NKort N EN EN EN91““,449W,,N r r W EN EN 10 M‘N“ ,4 4““ , RN“, *3“, N N\ /N ,N /N t; ELM) AN 3m tr w (E Rw53w ,Ehawkwkwamhw9 9 9 wherein the broken lines denote the points of attachment to the oxazepine ring to form a tricyclic group.
15. A compound selected from the group consisting of: 1001357339 II-l 5—morpholino(4—(trifluoromethy1)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepine; N—benzyl(4—(trifluoromethy1)pheny1)-2,3-dihydrobenzo [f] [1 ,4]oxazepin—S—amine; 5-(pyrrolidin-1—y1)(4-(trifluoromethy1)pheny1)~2,3- 11—3 dihydrobenzo [1] [1 ,4] oxazepine; N—cyclopropy1—7-(4-(trifluoromethy1)pheny1)-2,3-dihydrobenzo [f] [1 ,4]oxazepin—5— 11-4 amine; ' N-benzyl—N-methy1—7—(4—(trifluoromethyl)pheny1)—2,3 - 11—5 dihydrobenzo [f] [1 ,4] oxazepin—S -amine; N—((3 —flu0r0pyridin—2—y1)methy1)—7-(4-(trifluoromethy1)pheny1)—2,3— 11—9 dihydrobenzofi] [1 ,4]0xazepin—5—amine; N—(pyridin~2—y1methy1)~7—(4—(trifluor0methy1)pheny1)—2,3 — 11‘ 1 0 dihydrobenzofl] [ l ,4] oxazepin—S—amine; N—(cyclopropylmethyl)—7—(4—(trifluoromethyl)phenyl)—2,3 — 11—1 1 dihydrobenzo[f] [1 ,4] oxazepin-S—amine; (S)—tert—butyl 1~(74(4-(t1‘ifluoromethyl)pheny1)—2,3 —dihyd1‘0benzo [1] [1 ,4]0xazepin—5— 11—1 3 yl)pyrr01idin—3—y1carbamatc; N~(2—( 1 H—imidazol— 1 —yl)ethyl)(4—(trifluoromcthyl)phenyl)—2,3 — 11—1 4 dihydrobenzofi] [1 ,4] n—S-amine; (S)-N,N—dimethyl—1 —(7—(4—(11‘iflLloromethy1)pheny1)—2,3— 11—15 dihyd1‘0benzo[f][1 zepin—5—yl)pyrrolidin—3~amine; N—(py1‘idin—2-y1)~7-(4—(trifluo1‘omethyl)phcny1)—2,3—dihydr0bcnzo[1][1 ,4]0xachin- H— 1 9 S—aminc; N—(2—(py1‘idin—2—yloxy)cthyl)—7-(4—(trifluoromethy1)phenyl)—2,3 — H 20- dihydrobenzofi] [1 ,4]oxazepin—S—amine; N—(2—phen0xyethyl)-7—(4—(triflu0r0methy1)phenyl)—2,3 — 11—22 dihydrobenzo[fl [1 ,4]oxazepin-S—amine; N—(2-(2-ch10rophenoxy)ethy1)—7—(4—(triflu0romethyl)pheny1)-2,3 - II-24 dihydrobenzo [f] [1 zepinamine; —{ 7-(4—(trifluoromethy1)phenyl)-N-((6—(trifluoromethy1)pyridin—2-y1)methy1)-2,3 - 11-25 . . .
NZ618684A 2011-07-01 2012-06-29 Oxazepines as ion channel modulators NZ618684B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161503980P 2011-07-01 2011-07-01
US61/503,980 2011-07-01
PCT/US2012/045021 WO2013006463A1 (en) 2011-07-01 2012-06-29 Oxazepines as ion channel modulators

Publications (2)

Publication Number Publication Date
NZ618684A NZ618684A (en) 2016-02-26
NZ618684B2 true NZ618684B2 (en) 2016-05-27

Family

ID=

Similar Documents

Publication Publication Date Title
AU2012279214B2 (en) Oxazepines as ion channel modulators
EP2588197B1 (en) Fused heterocyclic compounds as ion channel modulators
EP2707361B1 (en) Fused heterocyclic compounds as sodium channel modulators
DK2464645T3 (en) CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS
EP2726466B1 (en) Fused benzoxazepinones as ion channel modulators
US20100125091A1 (en) Substituted heterocyclic compounds as ion channel modulators
AU2015224425B2 (en) Fused benzoxazepinones as ion channel modulators
US9920018B2 (en) Fused heterocyclic compounds as ion channel modulators
NZ618684B2 (en) Oxazepines as ion channel modulators
OA20251A (en) Fused benzoxazepinones as ion channel modulators